ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2,1,Headache,Headaches NEC,Headaches,Nerv,N
2,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2,3,Mood altered,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
3,1,Anaphylactoid reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
4,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
5,1,Cerebrovascular disorder,Central nervous system vascular disorders NEC,Central nervous system vascular disorders,Nerv,N
6,1,Congenital multiplex arthrogryposis,Musculoskeletal disorders congenital NEC,Musculoskeletal and connective tissue disorders congenital,Cong,N
7,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
7,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
8,1,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
9,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
10,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
11,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
12,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
12,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
13,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
13,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
14,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
15,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
15,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
15,3,Ketosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
15,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
16,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
16,2,Road traffic accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,Y
17,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
17,2,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
17,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
17,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
18,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
19,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
19,2,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
19,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
19,4,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
20,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
21,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
22,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
22,2,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
23,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
23,2,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
24,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
24,2,Headache,Headaches NEC,Headaches,Nerv,N
24,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
25,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
25,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
26,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
27,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
28,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
29,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
30,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
31,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
32,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
33,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
34,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
35,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
35,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
35,3,Headache,Headaches NEC,Headaches,Nerv,N
35,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
36,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
37,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
38,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
38,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
38,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
38,4,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
39,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
40,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
41,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
42,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
42,2,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
42,3,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
43,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
44,1,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,Y
45,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
45,2,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
45,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
45,4,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
46,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
47,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
47,2,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
48,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
48,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
48,3,Headache,Headaches NEC,Headaches,Nerv,N
48,4,Hunger,Feelings and sensations NEC,General system disorders NEC,Genrl,N
48,5,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
48,6,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
48,7,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
49,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
50,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
50,2,Device failure,Device issues NEC,Device issues,Prod,N
51,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
51,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
51,3,Nervousness,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
52,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
53,1,Headache,Headaches NEC,Headaches,Nerv,N
54,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
55,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
56,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
57,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
58,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
59,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
59,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
60,1,Agnosia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
60,2,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
60,3,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
60,4,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
60,5,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
60,6,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
60,7,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
60,8,Emotional disorder,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
60,9,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
60,10,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
60,11,Loss of libido,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
60,12,Menstruation irregular,Menstruation and uterine bleeding NEC,Menstrual cycle and uterine bleeding disorders,Repro,N
60,13,Personality disorder,Personality disorders NEC,Personality disorders and disturbances in behaviour,Psych,N
60,14,Somatic symptom disorder,Somatic symptom disorders,Somatic symptom and related disorders,Psych,N
60,15,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
61,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
62,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
63,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
64,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
65,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
66,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
67,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
68,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
68,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
68,3,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
68,4,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
68,5,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
69,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
69,2,Eye pruritus,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
69,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
69,4,Injection site infection,Infections NEC,Infections - pathogen unspecified,Infec,N
69,5,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
69,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
70,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
71,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
71,2,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
71,3,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
72,1,Candida infection,Candida infections,Fungal infectious disorders,Infec,N
72,2,Cystitis,Urinary tract infections,Infections - pathogen unspecified,Infec,N
72,3,Fungal infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
72,4,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
73,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
74,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
74,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
74,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
74,4,Headache,Headaches NEC,Headaches,Nerv,N
74,5,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
74,6,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
75,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
76,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
77,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
78,1,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
78,2,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
79,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
80,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
80,2,Device failure,Device issues NEC,Device issues,Prod,N
80,3,Headache,Headaches NEC,Headaches,Nerv,N
80,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
81,1,Skin erosion,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
82,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
83,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
84,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
85,1,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
86,1,Immune thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
86,2,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
87,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
87,2,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
87,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
87,4,Paranoia,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
88,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
89,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
89,2,Headache,Headaches NEC,Headaches,Nerv,N
89,3,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
89,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
90,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
91,1,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
92,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
93,1,Polyarthritis,Arthropathies NEC,Joint disorders,Musc,N
94,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
94,2,Ketonuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
95,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
96,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,Y
97,1,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
98,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
99,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
99,2,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
99,3,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
100,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
100,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
101,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
101,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
101,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
102,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
103,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
104,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
104,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
104,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
105,1,Skin test positive,Immunology skin tests NEC,Immunology and allergy investigations,Inv,N
106,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
106,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
106,3,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
107,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
108,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
108,2,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
108,3,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
109,1,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
110,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
111,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
112,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
112,2,Inflammation,Inflammations,General system disorders NEC,Genrl,N
112,3,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
113,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
114,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
115,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
115,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
116,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
116,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
117,1,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
118,1,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
119,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
119,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
119,3,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
120,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
121,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
121,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
121,3,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
122,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
123,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
124,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
124,2,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
124,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
124,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
125,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
126,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
127,1,Completed suicide,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,Y
127,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
128,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
128,2,Laryngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
129,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
129,2,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
129,3,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
129,4,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
130,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
131,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
131,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
132,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
132,2,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
133,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
134,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
135,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
135,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
135,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
135,4,Hair disorder,Pilar disorders NEC,Skin appendage conditions,Skin,N
136,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
136,2,Nervous system disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
137,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
138,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
138,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
138,3,Furuncle,Staphylococcal infections,Bacterial infectious disorders,Infec,N
138,4,Headache,Headaches NEC,Headaches,Nerv,N
138,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
138,6,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
138,7,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
139,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
140,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
141,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
141,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
141,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
142,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
142,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
143,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
144,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
145,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
145,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
145,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
146,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
146,2,Agnosia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
146,3,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
146,4,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
146,5,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
146,6,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
146,7,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
146,8,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
146,9,Distractibility,Cognitive and attention disorders and disturbances NEC,Cognitive and attention disorders and disturbances,Psych,N
146,10,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
146,11,Loss of libido,Sexual desire disorders,"Sexual dysfunctions, disturbances and gender identity disorders",Psych,N
146,12,Menstruation irregular,Menstruation and uterine bleeding NEC,Menstrual cycle and uterine bleeding disorders,Repro,N
146,13,Personality change,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
146,14,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
146,15,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
147,1,Facial pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
147,2,Migraine,Migraine headaches,Headaches,Nerv,N
147,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
147,4,Photopsia,Visual disorders NEC,Vision disorders,Eye,N
147,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
148,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
148,2,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
148,3,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
148,4,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
148,5,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
149,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
150,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
150,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
151,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
151,2,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
151,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
151,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
151,5,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
151,6,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
151,7,Ear disorder,Ear disorders NEC,Aural disorders NEC,Ear,N
151,8,Haemorrhoids,Haemorrhoids and gastrointestinal varices (excl oesophageal),Gastrointestinal vascular conditions,Gastr,N
151,9,Headache,Headaches NEC,Headaches,Nerv,N
151,10,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
151,11,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
151,12,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
151,13,Mood altered,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
151,14,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
151,15,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
152,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
152,2,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
152,3,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
152,4,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
152,5,Coordination abnormal,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
152,6,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
152,7,Derealisation,Perception disturbances NEC,Disturbances in thinking and perception,Psych,N
152,8,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
152,9,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
152,10,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
152,11,Fungal infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
152,12,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
152,13,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
152,14,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
152,15,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
152,16,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
152,17,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
152,18,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
152,19,Social avoidant behaviour,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
152,20,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
153,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
153,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
153,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
153,4,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
154,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
155,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
155,2,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
155,3,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
155,4,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
155,5,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
155,6,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
155,7,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
155,8,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
155,9,Headache,Headaches NEC,Headaches,Nerv,N
155,10,Hypersomnia,Narcolepsy and hypersomnia,Sleep disturbances (incl subtypes),Nerv,N
155,11,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
155,12,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
155,13,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
155,14,Menstruation irregular,Menstruation and uterine bleeding NEC,Menstrual cycle and uterine bleeding disorders,Repro,N
155,15,Mood swings,Fluctuating mood symptoms,Mood disorders and disturbances NEC,Psych,N
155,16,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
155,17,Myalgia,Muscle pains,Muscle disorders,Musc,N
155,18,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
155,19,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
156,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
156,2,Injection site oedema,Injection site reactions,Administration site reactions,Genrl,N
156,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
156,4,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
157,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
157,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
157,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
158,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
158,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
159,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
159,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
160,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
160,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
160,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
161,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
162,1,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
162,2,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
162,3,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
163,1,Cataract diabetic,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
164,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
164,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
165,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
165,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
166,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
166,2,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
166,3,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
167,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
167,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
167,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
167,4,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
168,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
169,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
169,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
170,1,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
171,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
171,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
172,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
172,2,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
173,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
174,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
174,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
174,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
174,4,Headache,Headaches NEC,Headaches,Nerv,N
174,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
174,6,Panic attack,Panic attacks and disorders,Anxiety disorders and symptoms,Psych,N
175,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
175,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
175,3,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
175,4,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
175,5,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
175,6,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
175,7,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
175,8,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
175,9,Hangover,Feelings and sensations NEC,General system disorders NEC,Genrl,N
175,10,Headache,Headaches NEC,Headaches,Nerv,N
175,11,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
175,12,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
175,13,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
175,14,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
176,1,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
177,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
177,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
177,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
178,1,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
178,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
178,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
178,4,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
179,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
180,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
181,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
182,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
182,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
182,3,Headache,Headaches NEC,Headaches,Nerv,N
182,4,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
182,5,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
182,6,Mood swings,Fluctuating mood symptoms,Mood disorders and disturbances NEC,Psych,N
182,7,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
182,8,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
183,1,Dyschezia,Gastrointestinal dyskinetic disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
184,1,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,Y
185,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
185,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
186,1,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
186,2,Necrotising fasciitis,Muscle and soft tissue infections,Infections - pathogen unspecified,Infec,N
187,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
187,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
188,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
188,2,Decreased insulin requirement,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
188,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
188,4,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
188,5,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
188,6,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
188,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
188,8,Neuralgia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
188,9,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
188,10,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
189,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
190,1,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
190,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
191,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
192,1,Lacrimation increased,Lacrimation disorders,Eye disorders NEC,Eye,N
192,2,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
193,1,Device failure,Device issues NEC,Device issues,Prod,N
193,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
194,1,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
195,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
196,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
196,2,Tension headache,Headaches NEC,Headaches,Nerv,N
197,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
197,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
197,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
198,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
198,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
199,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
200,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
201,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
202,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
203,1,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
203,2,Lipohypertrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
203,3,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
204,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
205,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
205,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
206,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
207,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
208,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
209,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
210,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
211,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
211,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
212,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
213,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
214,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
214,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
214,3,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
214,4,Dysmenorrhoea,Menstruation and uterine bleeding NEC,Menstrual cycle and uterine bleeding disorders,Repro,N
214,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
214,6,Headache,Headaches NEC,Headaches,Nerv,N
214,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
215,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
215,2,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
215,3,Paranoia,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
215,4,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
216,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
216,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
216,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
216,4,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
217,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
217,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
218,1,Injection site irritation,Injection site reactions,Administration site reactions,Genrl,N
218,2,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
218,3,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
219,1,Diabetic ketoacidotic hyperglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
220,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
221,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
221,2,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
222,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
222,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
223,1,Device leakage,Device issues NEC,Device issues,Prod,N
223,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
223,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
224,1,Injection site irritation,Injection site reactions,Administration site reactions,Genrl,N
225,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
225,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
226,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
226,2,Device failure,Device issues NEC,Device issues,Prod,N
227,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
227,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
227,3,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
227,4,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
228,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
229,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
230,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
231,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
231,2,Device failure,Device issues NEC,Device issues,Prod,N
232,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
233,1,Eye pruritus,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
233,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
233,3,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
233,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
233,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
234,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
235,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
235,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
235,3,Ulcer,Ulcers NEC,Tissue disorders NEC,Genrl,N
236,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
237,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
238,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
239,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
240,1,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
240,2,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
241,1,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
241,2,Hyperaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
241,3,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
242,1,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
243,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
244,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
244,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
245,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
246,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
247,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
247,2,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
248,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
249,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
249,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
249,3,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
249,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
250,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
250,2,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
250,3,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
250,4,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
250,5,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
251,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
251,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
252,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
252,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
253,1,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
253,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
254,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
254,2,Injection site vesicles,Injection site reactions,Administration site reactions,Genrl,N
254,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
254,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
255,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
255,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
256,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
257,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
257,2,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
258,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
258,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
259,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
259,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
260,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
261,1,Small for dates baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
262,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
262,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
262,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
263,1,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
263,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
264,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
264,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
264,3,Ketonuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
265,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
265,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
265,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
266,1,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
266,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
267,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
267,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
268,1,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
269,1,Coma,Coma states,Neurological disorders NEC,Nerv,N
269,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
270,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
270,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
271,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
271,2,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
272,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
273,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
273,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
273,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
273,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
273,5,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
273,6,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
274,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
274,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
275,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
275,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
275,3,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
276,1,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
277,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
278,1,Pregnancy,"Normal pregnancy, labour and delivery","Pregnancy, labour, delivery and postpartum conditions",Preg,N
278,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
279,1,Injection site infection,Infections NEC,Infections - pathogen unspecified,Infec,N
279,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
280,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
280,2,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
281,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
281,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
282,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
282,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
282,3,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
283,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
283,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
284,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
285,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
286,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
287,1,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
287,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
288,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
288,2,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
288,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
288,4,Periorbital swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
288,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
289,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
289,2,Nervous system disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
290,1,Gait inability,Gait disturbances,General system disorders NEC,Genrl,N
291,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
292,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
292,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
293,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
293,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
293,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
293,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
294,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
294,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
295,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
295,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
295,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
295,4,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
295,5,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
295,6,Premature labour,Labour onset and length abnormalities,Maternal complications of labour and delivery,Preg,N
296,1,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
297,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
297,2,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
298,1,Vulvovaginal discomfort,Vulvovaginal signs and symptoms,Vulvovaginal disorders (excl infections and inflammations),Repro,N
299,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
300,1,Arthropathy,Arthropathies NEC,Joint disorders,Musc,N
300,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
300,3,Groin pain,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
300,4,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
300,5,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
301,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
301,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
301,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
302,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
303,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
304,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
304,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
304,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
305,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
305,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
305,3,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
305,4,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
305,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
305,6,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
305,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
305,8,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
306,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
307,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
307,2,Therapeutic response increased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
308,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
309,1,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
309,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
309,3,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
309,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
310,1,Biopsy,Histopathology procedures NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
310,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
310,3,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
310,4,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
310,5,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
310,6,Conjunctivitis,Eye and eyelid infections,Infections - pathogen unspecified,Infec,N
310,7,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
310,8,Haemorrhagic urticaria,Urticarias,Angioedema and urticaria,Skin,N
310,9,Leukocytosis,Leukocytoses NEC,White blood cell disorders,Blood,N
310,10,Neuropathic ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
310,11,Nikolsky's sign,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
310,12,Oral disorder,Oral soft tissue disorders NEC,Oral soft tissue conditions,Gastr,N
310,13,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
310,14,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
310,15,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
310,16,Scab,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
310,17,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
310,18,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
310,19,Toxic epidermal necrolysis,Bullous conditions,Epidermal and dermal conditions,Skin,N
310,20,Varicella zoster virus infection,Herpes viral infections,Viral infectious disorders,Infec,N
311,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
311,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
312,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
312,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
313,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
313,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
314,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
314,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
314,3,Injection site vesicles,Injection site reactions,Administration site reactions,Genrl,N
314,4,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
315,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
315,2,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
315,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
315,4,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
315,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
315,6,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
315,7,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
315,8,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
315,9,Personality change,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
316,1,Haemorrhoids,Haemorrhoids and gastrointestinal varices (excl oesophageal),Gastrointestinal vascular conditions,Gastr,N
316,2,Headache,Headaches NEC,Headaches,Nerv,N
316,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
316,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
316,5,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
317,1,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
317,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
317,3,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
317,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
318,1,Optic disc disorder,Optic disc abnormalities NEC,"Ocular structural change, deposit and degeneration NEC",Eye,N
318,2,Papilloedema,Optic disc abnormalities NEC,"Ocular structural change, deposit and degeneration NEC",Eye,N
318,3,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
319,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
320,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,Y
321,1,Increased insulin requirement,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
322,1,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
323,1,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
324,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
324,2,Cardiac failure,Heart failures NEC,Heart failures,Card,Y
324,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
324,4,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
324,5,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
325,1,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
325,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
325,3,Swelling of eyelid,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
326,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
327,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
327,2,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
327,3,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
328,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
328,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
329,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
329,2,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
330,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
330,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
330,3,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
330,4,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
331,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
331,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
331,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
331,4,Headache,Headaches NEC,Headaches,Nerv,N
331,5,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
331,6,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
331,7,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
331,8,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
331,9,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
331,10,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
332,1,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
332,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
332,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
333,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
333,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
334,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
334,2,Pregnancy,"Normal pregnancy, labour and delivery","Pregnancy, labour, delivery and postpartum conditions",Preg,N
334,3,Premature rupture of membranes,Labour onset and length abnormalities,Maternal complications of labour and delivery,Preg,N
335,1,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
336,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
337,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
338,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
338,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
338,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
339,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
339,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
340,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
340,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
341,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
341,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
342,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
342,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
342,3,Device failure,Device issues NEC,Device issues,Prod,N
343,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
343,2,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
343,3,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
343,4,Sensory loss,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
344,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
345,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
345,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
345,3,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
346,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
346,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
347,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
347,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
348,1,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
348,2,Respiratory rate increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
349,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
349,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
349,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
349,4,Gastroenteritis viral,Viral infections NEC,Viral infectious disorders,Infec,N
349,5,Influenza,Influenza viral infections,Viral infectious disorders,Infec,N
349,6,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
349,7,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
350,1,Anti-insulin antibody,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
350,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
350,3,Injection site hypersensitivity,Injection site reactions,Administration site reactions,Genrl,N
350,4,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
351,1,Anti-insulin antibody positive,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
351,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
351,3,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
351,4,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
352,1,Lip oedema,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
352,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
352,3,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
352,4,Sensory loss,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
353,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
353,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
353,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
353,4,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
353,5,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
354,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
354,2,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
354,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
354,4,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
355,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
356,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
356,2,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
356,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
357,1,Device failure,Device issues NEC,Device issues,Prod,N
357,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
358,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
358,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
359,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
359,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
360,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
360,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
360,3,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
361,1,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
362,1,Anti-insulin antibody,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
362,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
362,3,Injection site hypersensitivity,Injection site reactions,Administration site reactions,Genrl,N
362,4,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
363,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
363,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
364,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
365,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
365,2,Cardiac failure,Heart failures NEC,Heart failures,Card,Y
365,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
365,4,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
365,5,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
365,6,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
366,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
366,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
366,3,Urine ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
367,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
367,2,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
368,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
368,2,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
369,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
369,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
370,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
370,2,Pregnancy,"Normal pregnancy, labour and delivery","Pregnancy, labour, delivery and postpartum conditions",Preg,N
370,3,Premature rupture of membranes,Labour onset and length abnormalities,Maternal complications of labour and delivery,Preg,N
371,1,Developmental hip dysplasia,Musculoskeletal and connective tissue disorders of limbs congenital,Musculoskeletal and connective tissue disorders congenital,Cong,N
371,2,Foetal distress syndrome,Foetal complications NEC,Foetal complications,Preg,N
371,3,Hypocalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
371,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
371,5,Inguinal hernia,Inguinal hernias,Abdominal hernias and other abdominal wall conditions,Gastr,N
371,6,Jaundice neonatal,Neonatal hepatobiliary disorders,Neonatal and perinatal conditions,Preg,N
371,7,Neonatal respiratory distress syndrome,Neonatal hypoxic conditions,Neonatal respiratory disorders,Resp,N
371,8,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
372,1,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
372,2,Device leakage,Device issues NEC,Device issues,Prod,N
372,3,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
372,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
373,1,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
373,2,Device leakage,Device issues NEC,Device issues,Prod,N
373,3,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
374,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
374,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
374,3,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
374,4,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
375,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
375,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
376,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
377,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
377,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
378,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
378,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
379,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
380,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
381,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
381,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
381,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
381,4,Impaired work ability,Disability issues,Lifestyle issues,SocCi,N
381,5,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
381,6,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
381,7,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
381,8,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
381,9,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
381,10,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
382,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
382,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
383,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
383,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
383,3,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
383,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
384,1,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
384,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
385,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
385,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
386,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
386,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
386,3,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
386,4,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
387,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
387,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
387,3,Petechiae,Purpura and related conditions,Skin vascular abnormalities,Skin,N
388,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
388,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
388,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
388,4,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
388,5,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
388,6,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
388,7,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
389,1,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
389,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
389,3,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
389,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
390,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
390,2,Device failure,Device issues NEC,Device issues,Prod,N
391,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
391,2,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
392,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
392,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
392,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
393,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
394,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
394,2,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
395,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
396,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
396,2,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
396,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
397,1,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
397,2,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
398,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
398,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
398,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
399,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
399,2,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
400,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
400,2,Urine ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
401,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
401,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
402,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
402,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
402,3,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
402,4,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
402,5,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
403,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
404,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
404,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
404,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
404,4,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
404,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
404,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
405,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
405,2,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
406,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
406,2,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
406,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
407,1,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
407,2,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
407,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
407,4,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
408,1,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
408,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
408,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
409,1,Injection site abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
410,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
410,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
410,3,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
410,4,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
410,5,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
411,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
411,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
412,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
412,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
412,3,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
413,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
413,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
413,3,Gastroenteritis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
414,1,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
415,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
416,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
416,2,Disorientation,Confusion and disorientation,Deliria (incl confusion),Psych,N
416,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
416,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
416,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
417,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
417,2,Injection site laceration,Injection site reactions,Administration site reactions,Genrl,N
417,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
417,4,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
417,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
418,1,Caudal regression syndrome,Musculoskeletal and connective tissue disorders of spine congenital,Musculoskeletal and connective tissue disorders congenital,Cong,N
419,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
419,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
420,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
420,2,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
421,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
421,2,Device leakage,Device issues NEC,Device issues,Prod,N
422,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
423,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
423,2,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
424,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
424,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
425,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
425,2,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
425,3,Headache,Headaches NEC,Headaches,Nerv,N
425,4,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
425,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
425,6,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
425,7,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
426,1,Anti-insulin antibody,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
426,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
427,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
427,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
427,3,Device failure,Device issues NEC,Device issues,Prod,N
428,1,Cerebral venous thrombosis,Cerebrovascular venous and sinus thrombosis,Central nervous system vascular disorders,Nerv,N
429,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
429,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
430,1,Apparent death,General signs and symptoms NEC,General system disorders NEC,Genrl,N
430,2,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
431,1,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
431,2,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
432,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
432,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
432,3,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
432,4,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
433,1,Tooth discolouration,Dental surface disorders,Dental and gingival conditions,Gastr,N
434,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
435,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
436,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
437,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
437,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
438,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
438,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
438,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
438,4,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
438,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
438,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
438,7,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
439,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
439,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
439,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
439,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
439,5,Mood altered,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
439,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
439,7,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
439,8,Restlessness,Increased physical activity levels,Changes in physical activity,Psych,N
439,9,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
439,10,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
440,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
440,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
440,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
440,4,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
441,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
442,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
443,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
444,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
444,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
445,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
445,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
446,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
446,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
447,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
447,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
448,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
448,2,Caesarean section,Obstetric therapeutic procedures,Obstetric and gynaecological therapeutic procedures,Surg,N
448,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
448,4,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
448,5,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
449,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
449,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
449,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
449,4,Pruritus genital,Reproductive tract signs and symptoms NEC,Reproductive tract disorders NEC,Repro,N
450,1,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
451,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
451,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
451,3,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
451,4,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
452,1,Device failure,Device issues NEC,Device issues,Prod,N
452,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
453,1,Diplopia,Visual disorders NEC,Vision disorders,Eye,N
453,2,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
453,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
453,4,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
453,5,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
454,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
455,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
456,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
456,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
457,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
457,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
457,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
458,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
459,1,Device failure,Device issues NEC,Device issues,Prod,N
459,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
459,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
459,4,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
460,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
460,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
461,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
461,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
461,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
461,4,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
461,5,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
462,1,Blood potassium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
462,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
462,3,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
462,4,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
462,5,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
462,6,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
463,1,Device failure,Device issues NEC,Device issues,Prod,N
463,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
464,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
465,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
466,1,Device failure,Device issues NEC,Device issues,Prod,N
466,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
467,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
467,2,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
467,3,Device failure,Device issues NEC,Device issues,Prod,N
467,4,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
467,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
468,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
468,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
469,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
469,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
469,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
469,4,Tonsillitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
470,1,Hypoglycaemic encephalopathy,Encephalopathies toxic and metabolic,Encephalopathies,Nerv,N
470,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,Y
471,1,Hypoglycaemic encephalopathy,Encephalopathies toxic and metabolic,Encephalopathies,Nerv,N
471,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
472,1,Hypoglycaemic encephalopathy,Encephalopathies toxic and metabolic,Encephalopathies,Nerv,N
472,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
473,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
474,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
474,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
474,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
474,4,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
475,1,Anaphylactic shock,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
476,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
476,2,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
476,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
477,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
477,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
477,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
478,1,Anaphylactic shock,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
479,1,Arrhythmia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
479,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
479,3,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
479,4,Vasculitic rash,Skin vasculitides,Skin vascular abnormalities,Skin,N
480,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
480,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
480,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
480,4,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
480,5,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
480,6,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
480,7,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
480,8,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
481,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
481,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
482,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
482,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
483,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
483,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
483,3,Generalised oedema,Oedema NEC,General system disorders NEC,Genrl,N
484,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
484,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
485,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
485,2,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
486,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
487,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
487,2,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
487,3,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
487,4,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
487,5,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
488,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
489,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
490,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
490,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
491,1,Device failure,Device issues NEC,Device issues,Prod,N
491,2,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
492,1,Idiopathic urticaria,Urticarias,Angioedema and urticaria,Skin,N
493,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
493,2,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
494,1,Device failure,Device issues NEC,Device issues,Prod,N
494,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
495,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
495,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
496,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
496,2,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
496,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
496,4,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
497,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
497,2,Increased insulin requirement,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
498,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
498,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
498,3,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
498,4,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
499,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
500,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
501,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
501,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
501,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
502,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
503,1,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
503,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
504,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
504,2,Headache,Headaches NEC,Headaches,Nerv,N
504,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
505,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
505,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
505,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
505,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
505,5,Skin mass,Skin and subcutaneous conditions NEC,Skin and subcutaneous tissue disorders NEC,Skin,N
506,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
506,2,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
507,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
508,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
508,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
508,3,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
509,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
509,2,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
509,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
509,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
509,5,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
509,6,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
510,1,Device failure,Device issues NEC,Device issues,Prod,N
510,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
511,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
512,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
512,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
512,3,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
513,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
513,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
513,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
513,4,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
513,5,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
514,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
514,2,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
515,1,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
515,2,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
516,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
516,2,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
516,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
517,1,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
518,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
519,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
520,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
520,2,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
520,3,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
521,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
521,2,Device failure,Device issues NEC,Device issues,Prod,N
522,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
522,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
523,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
524,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
524,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
525,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
525,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
526,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
526,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
526,3,Polyhydramnios,Amniotic fluid and cavity disorders of pregnancy NEC,"Placental, amniotic and cavity disorders (excl haemorrhages)",Preg,N
527,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
527,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
527,3,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
527,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
528,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
528,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
528,3,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
528,4,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
529,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
529,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
530,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
531,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
531,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
532,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
532,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
533,1,Sudden death,Death and sudden death,Fatal outcomes,Genrl,Y
534,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
535,1,Skin hyperpigmentation,Hyperpigmentation disorders,Pigmentation disorders,Skin,N
536,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
537,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
537,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
538,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
539,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,Y
540,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
540,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
541,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
541,2,Hypoglycaemia neonatal,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
541,3,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
542,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
542,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
542,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
542,4,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
543,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
543,2,Exercise tolerance decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
543,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
544,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
544,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
545,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
545,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
545,3,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
546,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
547,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
547,2,Inflammation,Inflammations,General system disorders NEC,Genrl,N
547,3,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
547,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
548,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
548,2,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
549,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
549,2,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
549,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
549,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
549,5,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
549,6,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
549,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
549,8,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
549,9,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
549,10,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
549,11,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
550,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
551,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
551,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
551,3,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
552,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
552,2,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
553,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
553,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
554,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
555,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
555,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
556,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
556,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
556,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
557,1,Arteriosclerosis,Non-site specific necrosis and vascular insufficiency NEC,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
558,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
558,2,Device issue,Device issues NEC,Device issues,Prod,N
558,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
558,4,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
559,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
559,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
560,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
560,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
561,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
561,2,Vanishing twin syndrome,Stillbirth and foetal death,Abortions and stillbirth,Preg,N
562,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
562,2,Product contamination,Product contamination and sterility issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
562,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
563,1,Arteriosclerosis,Non-site specific necrosis and vascular insufficiency NEC,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
564,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
564,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
565,1,Device difficult to use,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
565,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
565,3,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
565,4,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
566,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
567,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
567,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
567,3,Incoherent,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
567,4,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
568,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
568,2,Complication associated with device,Complications associated with device NEC,Complications associated with device,Genrl,N
569,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
569,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
570,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
570,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
571,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
571,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
572,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
572,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
573,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
573,2,Urine ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
574,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
575,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
575,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
575,3,Urine ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
576,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
576,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
576,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
576,4,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
577,1,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
577,2,Injection site vesicles,Injection site reactions,Administration site reactions,Genrl,N
577,3,Miliaria,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
577,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
578,1,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
578,2,Injection site vesicles,Injection site reactions,Administration site reactions,Genrl,N
579,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
579,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
580,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
581,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
581,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
582,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
582,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
582,3,Eructation,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
582,4,Gait inability,Gait disturbances,General system disorders NEC,Genrl,N
582,5,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
582,6,Hyperchlorhydria,Gastrointestinal mucosal dystrophies and secretion disorders,Gastrointestinal conditions NEC,Gastr,N
582,7,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
582,8,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
582,9,Loss of control of legs,Gait disturbances,General system disorders NEC,Genrl,N
582,10,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
582,11,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
583,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
583,2,Diabetic foot,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
584,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
584,2,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
585,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
585,2,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
585,3,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
585,4,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
585,5,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
585,6,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
585,7,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
585,8,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
585,9,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
585,10,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
585,11,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
585,12,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
585,13,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
585,14,Impatience,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
585,15,Mood swings,Fluctuating mood symptoms,Mood disorders and disturbances NEC,Psych,N
585,16,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
585,17,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
585,18,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
585,19,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
585,20,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
585,21,Retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
585,22,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
585,23,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
585,24,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
585,25,Vitreous haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
585,26,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
585,27,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
585,28,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
585,29,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
586,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
586,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
586,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
586,4,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
587,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
587,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
587,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
588,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
588,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
588,3,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
588,4,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
588,5,Stent placement,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
588,6,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
589,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
589,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
589,3,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
589,4,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
589,5,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
590,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
591,1,Cataract subcapsular,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
591,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
592,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
592,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
592,3,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
593,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
593,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
593,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
593,4,Product colour issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
594,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
594,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
594,3,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
594,4,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
594,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
594,6,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
594,7,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
594,8,Urinary tract infection bacterial,Bacterial infections NEC,Bacterial infectious disorders,Infec,Y
595,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
596,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
596,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
597,1,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
597,2,Kidney infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
597,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
598,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
598,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
599,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
599,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
600,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
601,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
601,2,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
601,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
601,4,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
601,5,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
602,1,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
603,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
603,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
604,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
604,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
604,3,Refusal of treatment by patient,Social issues NEC,Lifestyle issues,SocCi,N
604,4,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
605,1,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
605,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
606,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,Y
606,2,Glycosylated haemoglobin abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
606,3,Sudden death,Death and sudden death,Fatal outcomes,Genrl,Y
607,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
607,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
607,3,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
608,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,Y
609,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
609,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
609,3,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
609,4,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
609,5,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
610,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
611,1,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
611,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
611,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
612,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
613,1,Catheter site related reaction,Implant and catheter site reactions,Administration site reactions,Genrl,N
613,2,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
614,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
615,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
615,2,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
615,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
616,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
617,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
617,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
617,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
618,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
619,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
620,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
620,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
620,3,Pancreatitis chronic,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
621,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
621,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
622,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
622,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
623,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
623,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
623,3,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
624,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
624,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
624,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
625,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
625,2,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
626,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
626,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
627,1,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
628,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
629,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
629,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
629,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
630,1,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
630,2,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
630,3,Seizure like phenomena,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
631,1,Deformity,General signs and symptoms NEC,General system disorders NEC,Genrl,N
631,2,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
632,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
633,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
634,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
635,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
635,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
636,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
636,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
636,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
637,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
638,1,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
638,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
639,1,Diabetic ketosis,Diabetic complications NEC,Diabetic complications,Metab,N
639,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
639,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
640,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
641,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
641,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
642,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
642,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
642,3,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
642,4,Urine ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
643,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
643,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
644,1,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
645,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
645,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
645,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
645,4,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
646,1,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
647,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
647,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
648,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
648,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
648,3,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
648,4,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
649,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
649,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
649,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
650,1,Headache,Headaches NEC,Headaches,Nerv,N
650,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
651,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
651,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
651,3,Headache,Headaches NEC,Headaches,Nerv,N
651,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
651,5,Pseudomonas aeruginosa meningitis,Pseudomonal infections,Bacterial infectious disorders,Infec,N
651,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
652,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
652,2,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
652,3,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
652,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
652,5,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
652,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
652,7,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
652,8,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
653,1,Ocular retrobulbar haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
654,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
654,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
655,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
655,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
655,3,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
656,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
656,2,Headache,Headaches NEC,Headaches,Nerv,N
656,3,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
656,4,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
656,5,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
656,6,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
656,7,Pollakiuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
656,8,Thirst,Feelings and sensations NEC,General system disorders NEC,Genrl,N
656,9,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
657,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
657,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
657,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
658,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
658,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
658,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
658,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
659,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
659,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
660,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
660,2,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
661,1,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
662,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
662,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
662,3,Coma,Coma states,Neurological disorders NEC,Nerv,N
662,4,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
662,5,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
662,6,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
662,7,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
662,8,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
662,9,Nightmare,Parasomnias,Sleep disorders and disturbances,Psych,N
663,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
663,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
663,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
664,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
664,2,Communication disorder,Communications disorders,Communication disorders and disturbances,Psych,N
664,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
665,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
665,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
666,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
666,2,Head injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
666,3,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
666,4,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
667,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
667,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
667,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
667,4,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
667,5,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
667,6,Pneumothorax,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
667,7,Pollakiuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
667,8,Thirst,Feelings and sensations NEC,General system disorders NEC,Genrl,N
667,9,Urine output increased,Urinary tract function analyses NEC,Renal and urinary tract investigations and urinalyses,Inv,N
668,1,Abdominal mass,Abdominal findings abnormal,Gastrointestinal signs and symptoms,Gastr,N
668,2,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
668,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
668,4,Dysuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
668,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
669,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
670,1,Blood cholesterol increased,Cholesterol analyses,Lipid analyses,Inv,N
670,2,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
670,3,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
670,4,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
670,5,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
670,6,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
670,7,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
671,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
671,2,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
671,3,Lid sulcus deepened,"Orbital structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
671,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
671,5,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
672,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
672,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
672,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
672,4,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
672,5,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
672,6,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
672,7,Impatience,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
672,8,Mood altered,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
672,9,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
672,10,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
672,11,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
672,12,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
672,13,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
672,14,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
672,15,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
673,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
673,2,Cognitive disorder,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
673,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
673,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
673,5,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
673,6,Hyperinsulinaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
673,7,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
673,8,Loss of personal independence in daily activities,Disability issues,Lifestyle issues,SocCi,N
673,9,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
673,10,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
674,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
674,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
674,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
675,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
675,2,Cognitive disorder,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
675,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
675,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
675,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
675,6,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
675,7,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
675,8,Hyperinsulinaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
675,9,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
675,10,Loss of personal independence in daily activities,Disability issues,Lifestyle issues,SocCi,N
675,11,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
675,12,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
675,13,Renal function test abnormal,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
675,14,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
676,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
676,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
677,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
677,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
677,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
677,4,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
677,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
678,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
678,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
678,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
678,4,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
678,5,Mood swings,Fluctuating mood symptoms,Mood disorders and disturbances NEC,Psych,N
678,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
678,7,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
678,8,Retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
678,9,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
678,10,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
678,11,Vitreous haemorrhage,Choroid and vitreous haemorrhages and vascular disorders,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
678,12,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
679,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
680,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
680,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
681,1,General symptom,General signs and symptoms NEC,General system disorders NEC,Genrl,N
681,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
682,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
682,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
682,3,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
682,4,Headache,Headaches NEC,Headaches,Nerv,N
682,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
683,1,Delirium,Deliria,Deliria (incl confusion),Psych,N
683,2,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
683,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
683,4,Shock hypoglycaemic,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
684,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
685,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
685,2,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
686,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
686,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
687,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
688,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
688,2,Soft tissue injury,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
689,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
689,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
689,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
689,4,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
689,5,Impaired work ability,Disability issues,Lifestyle issues,SocCi,N
689,6,Stress,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
690,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
690,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
690,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
691,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
691,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
692,1,Lipodystrophy acquired,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
693,1,Device leakage,Device issues NEC,Device issues,Prod,N
693,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
694,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
694,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
695,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
695,2,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
696,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
696,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
696,3,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
697,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
697,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
697,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
697,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
697,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
697,6,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
697,7,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
697,8,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
697,9,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
698,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
698,2,Therapy change,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
699,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
700,1,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
700,2,Device difficult to use,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
700,3,Device occlusion,Device malfunction events NEC,Device issues,Prod,N
700,4,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
701,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
701,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
702,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
702,2,Product colour issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
702,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
703,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
703,2,Device difficult to use,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
703,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
703,4,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
703,5,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
704,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
704,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
705,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
705,2,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
705,3,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
705,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
705,5,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
705,6,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
706,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
706,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
707,1,Gastroenteritis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
708,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
708,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
708,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
708,4,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
708,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
709,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
709,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
710,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
710,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
711,1,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
711,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
712,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
713,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
713,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
713,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
714,1,Blood pressure systolic increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
714,2,Blood pressure systolic increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
715,1,Retinopathy proliferative,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
716,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
716,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
716,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
717,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
717,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
717,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
718,1,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
719,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
720,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
720,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
720,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
721,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
721,2,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
721,3,Hirsutism,Hypertrichoses,Skin appendage conditions,Skin,N
721,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
722,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
722,2,Device failure,Device issues NEC,Device issues,Prod,N
722,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
722,4,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
723,1,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
724,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
724,2,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
724,3,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
725,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
726,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
726,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
727,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
727,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
727,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
728,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
728,2,Injection site hypersensitivity,Injection site reactions,Administration site reactions,Genrl,N
728,3,Injection site macule,Injection site reactions,Administration site reactions,Genrl,N
728,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
728,5,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
728,6,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
728,7,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
728,8,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
729,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
730,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
731,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
731,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
731,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
731,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
731,5,Polydipsia,Fluid intake increased,Electrolyte and fluid balance conditions,Metab,N
731,6,Polyuria,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
732,1,Headache,Headaches NEC,Headaches,Nerv,N
733,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
733,2,Body temperature decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
733,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
733,4,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
734,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
734,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
734,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
734,4,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
734,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
734,6,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
734,7,Product contamination,Product contamination and sterility issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
734,8,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
734,9,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
734,10,Psychological trauma,Psychiatric symptoms NEC,Psychiatric and behavioural symptoms NEC,Psych,N
734,11,Restlessness,Increased physical activity levels,Changes in physical activity,Psych,N
734,12,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
735,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
735,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
735,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
735,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
736,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
736,2,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
737,1,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
737,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
737,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
738,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
738,2,Diabetic neuropathy,Chronic polyneuropathies,Peripheral neuropathies,Nerv,N
738,3,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
738,4,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
738,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
739,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
739,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
739,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
740,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
740,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
740,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
740,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
741,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
742,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
743,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
743,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
744,1,Diabetic complication,Diabetic complications NEC,Diabetic complications,Metab,N
744,2,Leg amputation,Limb therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
745,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
745,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
745,3,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
746,1,Catheter site related reaction,Implant and catheter site reactions,Administration site reactions,Genrl,N
746,2,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
747,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
748,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
749,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
749,2,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
750,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
750,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
750,3,Pancreatitis relapsing,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
750,4,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
751,1,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
751,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
752,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
752,2,Pancreatic carcinoma,Pancreatic neoplasms malignant (excl islet cell and carcinoid),Gastrointestinal neoplasms malignant and unspecified,Neopl,N
753,1,Acne,Acnes,Skin appendage conditions,Skin,N
753,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
753,3,Product colour issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
753,4,Prostate cancer,Prostatic neoplasms malignant,Reproductive neoplasms male malignant and unspecified,Neopl,N
754,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
755,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
755,2,Cold sweat,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
755,3,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
756,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
756,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
756,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
756,4,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
756,5,Skin infection,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
757,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
758,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
759,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
759,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
759,3,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
760,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
760,2,Coma,Coma states,Neurological disorders NEC,Nerv,N
760,3,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
761,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
761,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
761,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
762,1,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
763,1,Abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
763,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
764,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
764,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
764,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
765,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
765,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
766,1,Abdominal mass,Abdominal findings abnormal,Gastrointestinal signs and symptoms,Gastr,N
766,2,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
766,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
766,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
766,5,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
766,6,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
766,7,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
767,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
767,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
767,3,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
767,4,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
767,5,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
768,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
768,2,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
768,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
769,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
770,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
771,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
771,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
772,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
773,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
773,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
774,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
774,2,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
774,3,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
774,4,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
775,1,Anti-insulin antibody,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
775,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
775,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
776,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
776,2,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
777,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
777,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
778,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
778,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
779,1,Injection site necrosis,Injection site reactions,Administration site reactions,Genrl,N
780,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
780,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
780,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
781,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
781,2,Drug administered in wrong device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
782,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
782,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
782,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
783,1,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
784,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
784,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
784,3,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
785,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
786,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
786,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
787,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
788,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
788,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
788,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
789,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
789,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
790,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
790,2,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
791,1,Feeding disorder,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
792,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
792,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
793,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
793,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
793,3,Nephrolithiasis,Renal lithiasis,Urolithiases,Renal,N
793,4,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
794,1,Headache,Headaches NEC,Headaches,Nerv,N
795,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
795,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
795,3,Injection site discolouration,Injection site reactions,Administration site reactions,Genrl,N
795,4,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
795,5,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
796,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
796,2,Device leakage,Device issues NEC,Device issues,Prod,N
796,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
796,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
797,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
797,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
797,3,Pancreatic carcinoma,Pancreatic neoplasms malignant (excl islet cell and carcinoid),Gastrointestinal neoplasms malignant and unspecified,Neopl,N
798,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
798,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
798,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
799,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
799,2,Device failure,Device issues NEC,Device issues,Prod,N
799,3,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
799,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
800,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
800,2,Feeding disorder,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
800,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
800,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
801,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
801,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
801,3,Incorrect dosage administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
802,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
803,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
803,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
804,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
804,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
804,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
805,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
806,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
806,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
807,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
807,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
808,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
808,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
809,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
809,2,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
809,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
810,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
811,1,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
812,1,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
812,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
813,1,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
814,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
815,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
816,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
816,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
816,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
817,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
817,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
818,1,Diabetic complication,Diabetic complications NEC,Diabetic complications,Metab,N
818,2,Leg amputation,Limb therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
819,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
820,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
821,1,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
821,2,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
821,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
822,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
822,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
823,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
823,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
824,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
824,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
825,1,Catheter site related reaction,Implant and catheter site reactions,Administration site reactions,Genrl,N
825,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
825,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
825,4,Inflammation,Inflammations,General system disorders NEC,Genrl,N
826,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
826,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
826,3,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
826,4,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
827,1,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
828,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
828,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
828,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
829,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
829,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
829,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
830,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
830,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
830,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
831,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
831,2,Device issue,Device issues NEC,Device issues,Prod,N
832,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
833,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
833,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
834,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
834,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
834,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
834,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
835,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
835,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
835,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
835,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
836,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
836,2,Product lot number issue,Product label issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
837,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
838,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
839,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
839,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
839,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
839,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
839,5,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
840,1,Abdominal infection,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
840,2,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
840,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
840,4,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
840,5,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
841,1,Increased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
841,2,Lipodystrophy acquired,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
841,3,Ocular neoplasm,Ocular neoplasms malignancy unspecified,Ocular neoplasms,Neopl,N
842,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
842,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
843,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
844,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
844,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
845,1,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
846,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
847,1,Rheumatoid arthritis,Rheumatoid arthropathies,Joint disorders,Musc,N
848,1,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
849,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
849,2,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
850,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
850,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
850,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
851,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
852,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
852,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
852,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
852,4,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
852,5,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
853,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
853,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
854,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
854,2,Rheumatoid arthritis,Rheumatoid arthropathies,Joint disorders,Musc,N
855,1,Coma,Coma states,Neurological disorders NEC,Nerv,N
855,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
856,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
856,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
857,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
857,2,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
857,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
858,1,Retinal detachment,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
859,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
859,2,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
859,3,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
859,4,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
860,1,Age-related macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
860,2,Aneurysm,Aneurysms and dissections non-site specific,Aneurysms and artery dissections,Vasc,N
860,3,Maculopathy,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
860,4,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
860,5,Uveitis,"Iris and uveal tract infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
861,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
861,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
861,3,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
862,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
863,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
863,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
864,1,Atrioventricular block,Cardiac conduction disorders,Cardiac arrhythmias,Card,N
864,2,Product colour issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
864,3,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
864,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
865,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
865,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
865,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
865,4,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
866,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
866,2,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
866,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
867,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
867,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
868,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
868,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
868,3,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
869,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
869,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
869,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
869,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
870,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
870,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
870,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
871,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
871,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
871,3,Ketosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
871,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
872,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
873,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
873,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
873,3,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
873,4,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
874,1,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
874,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
875,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
876,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
877,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
877,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
877,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
877,4,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
877,5,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
878,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
878,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
879,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
879,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
879,3,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
880,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
880,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
880,3,Hyperglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
881,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
881,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
881,3,Headache,Headaches NEC,Headaches,Nerv,N
881,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
881,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
881,6,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
881,7,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
881,8,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
881,9,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
882,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
882,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
883,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
883,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
884,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
884,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
884,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
884,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
885,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
885,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
885,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
886,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
886,2,Toe amputation,Limb therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
886,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
887,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
887,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
887,3,Erosive duodenitis,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
887,4,Oesophagitis,Oesophagitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
887,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
888,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
889,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
889,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
889,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
889,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
889,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
889,6,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
889,7,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
890,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
890,2,Viral diarrhoea,Viral infections NEC,Viral infectious disorders,Infec,N
891,1,Dialysis,Renal therapeutic procedures,Renal and urinary tract therapeutic procedures,Surg,N
892,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
892,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
893,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
893,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
894,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
894,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
895,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
895,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
895,3,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
895,4,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
895,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
896,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
897,1,Blood alcohol increased,Toxicology laboratory analyses,Toxicology and therapeutic drug monitoring,Inv,N
897,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
897,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
897,4,Oesophagitis,Oesophagitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
897,5,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
897,6,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
897,7,Upper respiratory tract infection,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
898,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
898,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
899,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
900,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
901,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
901,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
901,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
902,1,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,Y
902,2,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
903,1,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
903,2,Lumbar vertebral fracture,Spinal fractures and dislocations,Bone and joint injuries,Inj&P,N
903,3,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
903,4,Pulmonary hypertension,Pulmonary hypertensions,Pulmonary vascular disorders,Resp,N
903,5,Renal cyst,Renal neoplasms,Renal disorders (excl nephropathies),Renal,N
903,6,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
903,7,Wound infection,Infections NEC,Infections - pathogen unspecified,Infec,N
904,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
905,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
905,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
905,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
906,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
906,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
907,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
907,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
907,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
908,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
908,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
909,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
909,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
910,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
910,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
911,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
911,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
911,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
912,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
912,2,Lipohypertrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
912,3,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
912,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
913,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
913,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
914,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
914,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
914,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
915,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
915,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
915,3,Gastroenteritis viral,Viral infections NEC,Viral infectious disorders,Infec,N
915,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
916,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
916,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
916,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
917,1,Atrial septal defect,Cardiac septal defects congenital,Cardiac and vascular disorders congenital,Cong,N
917,2,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
917,3,Hypoglycaemia neonatal,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
917,4,Jaundice neonatal,Neonatal hepatobiliary disorders,Neonatal and perinatal conditions,Preg,N
917,5,Neonatal respiratory distress syndrome,Neonatal hypoxic conditions,Neonatal respiratory disorders,Resp,N
917,6,Polycythaemia neonatorum,Polycythaemia (excl rubra vera),Red blood cell disorders,Blood,N
918,1,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
919,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
919,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
920,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,Y
920,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
920,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
921,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
921,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
921,3,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
921,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
922,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
922,2,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
922,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
922,4,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
923,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
923,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
924,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
924,2,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
925,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
926,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
926,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
927,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
927,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
927,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
927,4,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
928,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
928,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
928,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
929,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
930,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
930,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
931,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
931,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
931,3,Device issue,Device issues NEC,Device issues,Prod,N
931,4,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
931,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
931,6,Injury,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
932,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
932,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
932,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
933,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
933,2,Device failure,Device issues NEC,Device issues,Prod,N
933,3,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
933,4,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
933,5,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
933,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
933,7,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
933,8,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
933,9,Nerve injury,Nerve injuries NEC,Injuries NEC,Inj&P,N
934,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
934,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
935,1,Hepatic cancer,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
936,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
937,1,Spinal cord injury,Spinal cord injuries NEC,Injuries NEC,Inj&P,N
938,1,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
938,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
939,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
939,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
939,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
940,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
940,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
940,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
941,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
941,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
941,3,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
941,4,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
941,5,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
941,6,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
941,7,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
941,8,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
942,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
943,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
943,2,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
944,1,Anaphylactic shock,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
945,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
945,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
945,3,Intraocular pressure test,Ophthalmic function diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
946,1,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
946,2,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
947,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
947,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
948,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
948,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
948,3,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
948,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
949,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
949,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
949,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
950,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
950,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
950,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
950,4,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
950,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
950,6,Migraine,Migraine headaches,Headaches,Nerv,N
950,7,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
950,8,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
951,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
951,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
951,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
951,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
951,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
951,6,Urine ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
952,1,Femur fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
952,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
953,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
953,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
954,1,Device delivery system issue,Device issues NEC,Device issues,Prod,N
954,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
955,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
955,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
955,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
956,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
956,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
956,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
957,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
957,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
957,3,Blood pH decreased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
957,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
957,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
958,1,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
958,2,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
958,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
959,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
959,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
959,3,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
959,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
959,5,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
959,6,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
960,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
960,2,Device issue,Device issues NEC,Device issues,Prod,N
960,3,Diabetic coma,Coma states,Neurological disorders NEC,Nerv,N
960,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
960,5,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
961,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
961,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
961,3,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
962,1,Injection site necrosis,Injection site reactions,Administration site reactions,Genrl,N
963,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
963,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
963,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
963,4,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
964,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
964,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
965,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
966,1,Diabetic ketosis,Diabetic complications NEC,Diabetic complications,Metab,N
966,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
966,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
967,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
967,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
967,3,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
968,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
968,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
968,3,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
968,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
969,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
969,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
969,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
969,4,Urine ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
970,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
970,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
971,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
971,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
971,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
972,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
972,2,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
972,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
972,4,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
973,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
973,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
973,3,Injection site pustule,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
973,4,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
973,5,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
973,6,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
974,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
974,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
974,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
975,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
975,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
976,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
976,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
976,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
977,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
977,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
978,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
978,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
978,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
979,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
979,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
979,3,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
979,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
979,5,Urine ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
980,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
980,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
981,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
981,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
981,3,Urine ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
982,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
983,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
984,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
984,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
984,3,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
984,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
985,1,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
986,1,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
986,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
986,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
987,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
987,2,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
988,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
988,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
989,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
989,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
989,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
990,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
990,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
991,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
991,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
992,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
992,2,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
992,3,Device failure,Device issues NEC,Device issues,Prod,N
992,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
993,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
993,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
993,3,Viral upper respiratory tract infection,Viral infections NEC,Viral infectious disorders,Infec,N
994,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
994,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
994,3,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
994,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
995,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
995,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
995,3,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
996,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
996,2,Lower limb fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
996,3,Upper limb fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
997,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
997,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
997,3,Sensory loss,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
998,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
998,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
998,3,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
998,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
999,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
999,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
999,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
999,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
999,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1000,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1001,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1002,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1002,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1002,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1003,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1004,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1004,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1005,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1005,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1006,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1007,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1007,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1007,3,Episiotomy,Obstetric therapeutic procedures,Obstetric and gynaecological therapeutic procedures,Surg,N
1007,4,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1007,5,Forceps delivery,Obstetric therapeutic procedures,Obstetric and gynaecological therapeutic procedures,Surg,N
1008,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1008,2,Facial paralysis,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
1008,3,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1008,4,Hypoglycaemia neonatal,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1008,5,Positive airway pressure therapy,Respiratory tract therapeutic procedures NEC,Respiratory tract therapeutic procedures,Surg,N
1008,6,Resuscitation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
1009,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1009,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1010,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1011,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1012,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1012,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1013,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1013,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1014,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1014,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1014,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1015,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1016,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1016,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1017,1,Device difficult to use,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1017,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1017,3,Product lot number issue,Product label issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1017,4,Product odour abnormal,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1018,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1018,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1019,1,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1019,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1019,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1020,1,Device delivery system issue,Device issues NEC,Device issues,Prod,N
1020,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1020,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1021,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1021,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1022,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1023,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1023,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1023,3,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
1024,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
1024,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1024,3,Brain fog,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1024,4,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
1024,5,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1024,6,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1024,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1024,8,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
1024,9,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1024,10,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1024,11,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1024,12,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
1024,13,Weight fluctuation,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
1025,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1025,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1025,3,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1026,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
1026,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1027,1,Hypothalamo-pituitary disorder,Hypothalamic and pituitary disorders NEC,Hypothalamus and pituitary gland disorders,Endo,N
1027,2,Vascular dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
1028,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1028,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1029,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1030,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1030,2,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1031,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1031,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1031,3,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1032,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1033,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1033,2,Hyperglycaemic hyperosmolar nonketotic syndrome,Diabetic complications neurological,Diabetic complications,Metab,N
1033,3,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
1033,4,Urosepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1034,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1035,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1035,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1036,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1036,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1036,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1037,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1037,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1037,3,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1037,4,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1038,1,Delirium,Deliria,Deliria (incl confusion),Psych,N
1038,2,Injection site abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
1038,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
1039,1,Administration site infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1040,1,Prostate cancer,Prostatic neoplasms malignant,Reproductive neoplasms male malignant and unspecified,Neopl,N
1041,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1041,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1041,3,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1041,4,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1041,5,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1042,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1042,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1043,1,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1043,2,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1043,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1043,4,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1043,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1043,6,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1043,7,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1044,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1044,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1044,3,Post procedural infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1044,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1045,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1045,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1045,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1046,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
1046,2,Laryngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
1047,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1048,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1048,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1048,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1049,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1050,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1051,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1051,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1051,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1052,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1052,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1052,3,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1052,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1053,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1053,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1053,3,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1053,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1053,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1054,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1054,2,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
1055,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1055,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1055,3,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1055,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1055,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1056,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
1057,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1057,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1057,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1058,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1059,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1059,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1060,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1060,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1060,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1060,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1061,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1061,2,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1062,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1062,2,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1063,1,Abnormal weight gain,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
1063,2,Aortic valve stenosis,Aortic valvular disorders,Cardiac valve disorders,Card,N
1063,3,Arteriosclerosis,Non-site specific necrosis and vascular insufficiency NEC,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
1063,4,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1064,1,Accidental underdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1064,2,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1064,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1064,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1065,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1065,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1066,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1066,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1066,3,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1067,1,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1068,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1068,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1069,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1069,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1070,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1070,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1071,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1071,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1071,3,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1071,4,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1071,5,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1071,6,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1071,7,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1072,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1072,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1072,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1072,4,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1073,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1073,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1073,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1073,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1074,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1074,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1075,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1075,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1075,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1076,1,Acidosis,Mixed acid-base disorders,Acid-base disorders,Metab,N
1077,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1078,1,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1078,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1079,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1079,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1080,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1081,1,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1081,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1081,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1082,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1083,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1083,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1083,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1083,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1084,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1084,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1085,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1085,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1085,3,Lack of infusion site rotation,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1086,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1086,2,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1087,1,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
1087,2,Maculopathy,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
1088,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1088,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1089,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1089,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1089,3,Ketosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
1089,4,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1089,5,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1090,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1090,2,Gastroenteritis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
1090,3,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1090,4,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1090,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1091,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1091,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1092,1,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1093,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1094,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1095,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1096,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1097,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1098,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1099,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1100,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1100,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1101,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1101,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1101,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1101,4,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1101,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1101,6,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1102,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1102,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1102,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1103,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1104,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1104,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1105,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1106,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1107,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1107,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1108,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1108,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1109,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1109,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1109,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1109,4,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1109,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1110,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,Y
1111,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1111,2,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1112,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1113,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1113,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1113,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1113,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1114,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1114,2,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1115,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1115,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1116,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
1117,1,Musculoskeletal discomfort,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1117,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1118,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1118,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1119,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1119,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1119,3,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1119,4,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1119,5,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1119,6,Product packaging issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1120,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1120,2,Gingivitis,Dental and oral soft tissue infections,Infections - pathogen unspecified,Infec,N
1120,3,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1120,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1120,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1120,6,Toothache,Dental pain and sensation disorders,Dental and gingival conditions,Gastr,N
1120,7,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1121,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1121,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1122,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1123,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1123,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1123,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1123,4,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1123,5,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1123,6,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1123,7,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1124,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1124,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1125,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1125,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1126,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1126,2,Gastrointestinal infection,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
1126,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1126,4,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1127,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1127,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1127,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1128,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1128,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1128,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1128,4,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1128,5,Product contamination,Product contamination and sterility issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1129,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1129,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1130,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1131,1,Diabetes mellitus management,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
1132,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1132,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1133,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1133,2,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
1133,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1133,4,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1133,5,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
1133,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1134,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1135,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1136,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,Y
1136,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1137,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1137,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1137,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1138,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1139,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1139,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1140,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1140,2,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1140,3,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1140,4,Glossoptosis,Tongue signs and symptoms,Tongue conditions,Gastr,N
1140,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1141,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1141,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1142,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1142,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1143,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1143,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1144,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1145,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1146,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1146,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1147,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1148,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1148,2,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
1149,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1149,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1149,3,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1149,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1150,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1150,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1151,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1151,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1152,1,Brain injury,Structural brain disorders NEC,Structural brain disorders,Nerv,N
1152,2,Epilepsy,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1153,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1153,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1154,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1154,2,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
1154,3,Periarthritis,Joint related disorders NEC,Joint disorders,Musc,N
1154,4,Sticky skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1155,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1155,2,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1156,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1157,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1158,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1158,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1159,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1159,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1159,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1160,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1160,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1160,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1161,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1161,2,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1162,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1163,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
1163,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1164,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1164,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1165,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1165,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1165,3,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1166,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1166,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1166,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1166,4,Product odour abnormal,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1167,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1167,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1168,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1168,2,Device failure,Device issues NEC,Device issues,Prod,N
1168,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1168,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1169,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1169,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1169,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1169,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1170,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1170,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1170,3,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1170,4,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1170,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1171,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1171,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1171,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1171,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1171,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1172,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1172,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1173,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1173,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1173,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1174,1,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1174,2,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1175,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1176,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1176,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1177,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1177,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1177,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1178,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1178,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1178,3,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1178,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1178,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1179,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1179,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1180,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1181,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1181,2,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1181,3,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1182,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1182,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1183,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1183,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1183,3,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1183,4,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1183,5,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1183,6,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1184,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1184,2,Wrong dose,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1184,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1185,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1185,2,Device failure,Device issues NEC,Device issues,Prod,N
1186,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1187,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1188,1,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1188,2,Spinal fracture,Spinal fractures and dislocations,Bone and joint injuries,Inj&P,N
1189,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
1189,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1190,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1190,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1190,3,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1191,1,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
1191,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1191,3,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1192,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1192,2,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1193,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1193,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1194,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1194,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1195,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1195,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1195,3,Food poisoning,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
1195,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1196,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1197,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1197,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1198,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1199,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1199,2,Exposure via breast milk,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1199,3,Failed induction of labour,Failed labour,Maternal complications of labour and delivery,Preg,N
1200,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1200,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1201,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1201,2,Type 1 diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1202,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1202,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1203,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1203,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1203,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1203,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1204,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1204,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1204,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1204,4,Product contamination with body fluid,Product contamination and sterility issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1205,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1205,2,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1206,1,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1206,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1207,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1207,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1207,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1208,1,Autoimmune disorder,Autoimmune disorders NEC,Autoimmune disorders,Immun,N
1208,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1208,3,Learning disorder,Learning disorders,Cognitive and attention disorders and disturbances,Psych,N
1208,4,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1208,5,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1209,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1209,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1209,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
1210,1,Atrial septal defect,Cardiac septal defects congenital,Cardiac and vascular disorders congenital,Cong,N
1210,2,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1210,3,Hypoglycaemia neonatal,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1210,4,Jaundice neonatal,Neonatal hepatobiliary disorders,Neonatal and perinatal conditions,Preg,N
1210,5,Neonatal respiratory distress syndrome,Neonatal hypoxic conditions,Neonatal respiratory disorders,Resp,N
1210,6,Polycythaemia neonatorum,Polycythaemia (excl rubra vera),Red blood cell disorders,Blood,N
1211,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1212,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1212,2,Brachial plexus injury,Peripheral nerve injuries,Injuries NEC,Inj&P,N
1212,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1212,4,Diabetic ketosis,Diabetic complications NEC,Diabetic complications,Metab,N
1212,5,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1213,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1214,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1214,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1214,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1215,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1216,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1217,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
1217,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1218,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1218,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1218,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1218,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1219,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1219,2,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1220,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
1220,2,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1220,3,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
1221,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1222,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1222,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1222,3,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1222,4,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
1223,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1224,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1224,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1225,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1226,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1226,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1226,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1226,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1227,1,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
1227,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1228,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1228,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1228,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1229,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1229,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1229,3,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1229,4,Headache,Headaches NEC,Headaches,Nerv,N
1229,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1229,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1230,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1231,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1231,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1231,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1232,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1232,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1232,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1232,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1233,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1233,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1234,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1234,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1234,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1235,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1235,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1235,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1235,4,Shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1236,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1237,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1237,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1237,3,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
1237,4,Respiratory distress,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1238,1,Decreased insulin requirement,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1238,2,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
1238,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1238,4,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1238,5,Foetal hypokinesia,Foetal complications NEC,Foetal complications,Preg,N
1238,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1238,7,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
1238,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1239,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1239,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1240,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1240,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1240,3,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1241,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
1241,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1241,3,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1242,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1242,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1242,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1243,1,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1244,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1244,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1245,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1246,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1246,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1246,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1247,1,Anti-insulin antibody,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
1247,2,Bacterial sepsis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
1247,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1247,4,Injection site hypersensitivity,Injection site reactions,Administration site reactions,Genrl,N
1247,5,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1247,6,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
1247,7,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1248,1,Drug administered in wrong device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1248,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1248,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1248,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1248,5,Near death experience,Perception disturbances NEC,Disturbances in thinking and perception,Psych,N
1248,6,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1249,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1250,1,Bradycardia foetal,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
1250,2,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1250,3,Heterotaxia,Congenital disorders NEC,Congenital and hereditary disorders NEC,Cong,N
1250,4,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
1250,5,Vascular malformation,Vascular anomalies congenital NEC,Cardiac and vascular disorders congenital,Cong,N
1251,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1252,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1252,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1252,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1253,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1253,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1253,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1254,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1254,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1255,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1255,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1255,3,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1256,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1257,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1257,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1258,1,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
1258,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1259,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1259,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1259,3,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1259,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1260,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
1260,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1261,1,Critical illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1261,2,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
1261,3,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
1261,4,Surgery,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
1262,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1262,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1262,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1263,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1264,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1264,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1264,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1265,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1265,2,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
1266,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1266,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1267,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1268,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1269,1,Injection site pustule,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
1270,1,Duodenal ulcer haemorrhage,Duodenal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
1271,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1271,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1271,3,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1271,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1272,1,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
1272,2,Meningitis,Central nervous system and spinal infections,Infections - pathogen unspecified,Infec,N
1273,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1273,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1273,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1274,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1275,1,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1275,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1275,3,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1275,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1276,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1276,2,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1277,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
1277,2,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
1277,3,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
1277,4,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1277,5,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
1278,1,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1278,2,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1278,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1278,4,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1278,5,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1279,1,Affect lability,Affect alterations NEC,Mood disorders and disturbances NEC,Psych,N
1279,2,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
1279,3,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
1279,4,Daydreaming,Cognitive and attention disorders and disturbances NEC,Cognitive and attention disorders and disturbances,Psych,N
1279,5,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
1279,6,Social avoidant behaviour,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
1279,7,Social avoidant behaviour,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
1279,8,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
1280,1,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1280,2,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1281,1,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1282,1,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1283,1,Intercepted product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1284,1,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1285,1,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1285,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1286,1,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1287,1,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1287,2,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1287,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1288,1,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1288,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1289,1,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1289,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1290,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1291,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1291,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1291,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1291,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1292,1,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1293,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1293,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1293,3,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1293,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1294,1,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1295,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1295,2,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1296,1,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1297,1,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1298,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1298,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1298,3,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1298,4,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1299,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1299,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1300,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1300,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1301,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1302,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1302,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1302,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1303,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1303,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1303,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1303,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1304,1,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1305,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
1305,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1306,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1306,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1307,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1307,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1307,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1307,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1307,5,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1308,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
1308,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1309,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1310,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1310,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1311,1,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1311,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1311,3,Foetal renal imaging abnormal,Foetal and neonatal imaging procedures,Foetal and neonatal investigations,Inv,N
1311,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1311,5,Vacuum extractor delivery,Obstetric therapeutic procedures,Obstetric and gynaecological therapeutic procedures,Surg,N
1312,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
1313,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1313,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1314,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1314,2,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1314,3,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1315,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1315,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1316,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1316,2,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1317,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1317,2,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1318,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1318,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1318,3,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1319,1,Alcohol interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1319,2,Blood urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
1320,1,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1320,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1321,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1321,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1321,3,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1321,4,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1321,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1321,6,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1321,7,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1322,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1322,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1323,1,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
1323,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1324,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1324,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1324,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1325,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1325,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1326,1,Head injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
1326,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1326,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1327,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1327,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1327,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1328,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1328,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1328,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1329,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1330,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1330,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1330,3,Hyperemesis gravidarum,Maternal complications of pregnancy NEC,Maternal complications of pregnancy,Preg,N
1330,4,Premature delivery,Labour onset and length abnormalities,Maternal complications of labour and delivery,Preg,N
1331,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1331,2,Neck injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
1332,1,Hernia,Hernias NEC,General system disorders NEC,Genrl,N
1333,1,Macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
1334,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1334,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1334,3,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1335,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1335,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1335,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1336,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1337,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1338,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1338,2,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1338,3,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1338,4,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
1338,5,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1338,6,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1338,7,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1338,8,Localised infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1338,9,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1338,10,Product preparation issue,Product preparation errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1339,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
1339,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1340,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1341,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1342,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1342,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1342,3,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
1342,4,Lipohypertrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
1343,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1344,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1345,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1345,2,Pancreatic carcinoma,Pancreatic neoplasms malignant (excl islet cell and carcinoid),Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1346,1,Decreased insulin requirement,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1346,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1346,3,Increased insulin requirement,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1347,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1347,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1347,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1347,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1348,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1348,2,Device failure,Device issues NEC,Device issues,Prod,N
1348,3,Device information output issue,Device information output issues,Device issues,Prod,N
1348,4,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
1349,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1349,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1350,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1350,2,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1350,3,Product colour issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1350,4,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1351,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1352,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1352,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1353,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1354,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1354,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1354,3,Gastroenteritis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
1354,4,Influenza,Influenza viral infections,Viral infectious disorders,Infec,N
1354,5,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
1354,6,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1354,7,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
1355,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1356,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1356,2,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
1357,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1357,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1357,3,Viral diarrhoea,Viral infections NEC,Viral infectious disorders,Infec,N
1358,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1359,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1359,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1359,3,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1359,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1360,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1360,2,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1360,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1360,4,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1361,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1361,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1361,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1362,1,Atrial septal defect,Cardiac septal defects congenital,Cardiac and vascular disorders congenital,Cong,N
1362,2,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1362,3,Oculoauriculovertebral dysplasia,Musculoskeletal and connective tissue disorders of skull congenital,Musculoskeletal and connective tissue disorders congenital,Cong,N
1362,4,Plagiocephaly,Musculoskeletal and connective tissue disorders of skull congenital,Musculoskeletal and connective tissue disorders congenital,Cong,N
1362,5,Ventricular septal defect,Cardiac septal defects congenital,Cardiac and vascular disorders congenital,Cong,N
1363,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1363,2,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
1364,1,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
1365,1,Blood calcium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
1365,2,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1365,3,Blood magnesium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
1365,4,Chronic obstructive pulmonary disease,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
1365,5,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1366,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
1366,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1367,1,Device information output issue,Device information output issues,Device issues,Prod,N
1367,2,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1367,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1367,4,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1368,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1369,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1369,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1369,3,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
1370,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1370,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1370,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1370,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1371,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1371,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1372,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1373,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1373,2,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1374,1,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
1374,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1375,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1375,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1375,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1375,4,Stillbirth,Stillbirth and foetal death,Abortions and stillbirth,Preg,N
1376,1,Cold sweat,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1376,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1376,3,Muscle strain,"Muscle, tendon and ligament injuries",Injuries NEC,Inj&P,N
1376,4,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1377,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1378,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1378,2,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1378,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1378,4,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
1378,5,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1378,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1379,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1380,1,Product colour issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1380,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1381,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1381,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1382,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1382,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1383,1,Device colour issue,Device physical property and chemical issues,Device issues,Prod,N
1383,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1383,3,Product appearance confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1383,4,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1384,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1384,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1385,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1386,1,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
1386,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1386,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1387,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1387,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1387,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1387,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1388,1,Muscle strain,"Muscle, tendon and ligament injuries",Injuries NEC,Inj&P,N
1388,2,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
1389,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1389,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
1389,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1389,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1390,1,Cold sweat,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1390,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
1390,3,Formication,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1390,4,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
1390,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1390,6,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
1390,7,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1391,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1391,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1391,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1392,1,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
1392,2,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
1393,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1393,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1394,1,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
1394,2,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1395,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1395,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1396,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1397,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1398,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1399,1,Respiratory tract oedema,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
1399,2,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1400,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1401,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1401,2,Product lot number issue,Product label issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1402,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1402,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1402,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1402,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1402,5,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1403,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1403,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1403,3,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
1403,4,Metabolic acidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
1403,5,Supraventricular tachycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
1404,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1405,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1405,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1406,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1406,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1407,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1407,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1407,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1407,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1407,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1407,6,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1408,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1409,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1409,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1409,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1410,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1410,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1410,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1411,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1411,2,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1412,1,Knee operation,Joint therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
1413,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1413,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1413,3,Limb injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
1414,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
1414,2,Headache,Headaches NEC,Headaches,Nerv,N
1415,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1415,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1416,1,Adverse event,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1417,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1417,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1417,3,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1417,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1417,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1417,6,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1418,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
1419,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1419,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1419,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1420,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1420,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1420,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1421,1,Decreased insulin requirement,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1421,2,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
1421,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1421,4,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1421,5,Foetal hypokinesia,Foetal complications NEC,Foetal complications,Preg,N
1421,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1421,7,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
1421,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1422,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1422,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1423,1,Abnormal weight gain,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
1424,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1424,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1424,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1425,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1425,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1426,1,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
1426,2,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
1427,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1427,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1428,1,Abnormal loss of weight,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
1428,2,Hunger,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1428,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1428,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1429,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1429,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1429,3,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
1429,4,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1429,5,Foetal damage,Foetal complications NEC,Foetal complications,Preg,N
1429,6,Large for dates baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
1429,7,Recalled product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1430,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1430,2,Neonatal respiratory distress,Neonatal hypoxic conditions,Neonatal respiratory disorders,Resp,N
1431,1,Caesarean section,Obstetric therapeutic procedures,Obstetric and gynaecological therapeutic procedures,Surg,N
1431,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1431,3,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1431,4,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
1431,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1431,6,Premature delivery,Labour onset and length abnormalities,Maternal complications of labour and delivery,Preg,N
1431,7,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1432,1,Accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1432,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1432,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1432,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1433,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1434,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,Y
1435,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1436,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1436,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1436,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1436,4,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1436,5,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
1437,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1437,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1437,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1438,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1438,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
1438,3,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
1439,1,Oesophageal achalasia,Gastrointestinal dyskinetic disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
1440,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1440,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1441,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1442,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1442,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1443,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1443,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1443,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1443,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1444,1,Device delivery system issue,Device issues NEC,Device issues,Prod,N
1444,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
1444,3,Diabetic ketosis,Diabetic complications NEC,Diabetic complications,Metab,N
1444,4,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1445,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1445,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1446,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1447,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1447,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1448,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,Y
1448,2,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1448,3,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
1448,4,Caesarean section,Obstetric therapeutic procedures,Obstetric and gynaecological therapeutic procedures,Surg,N
1448,5,Cleft lip and palate,Palate disorders congenital,Gastrointestinal tract disorders congenital,Cong,N
1448,6,Drug abuse,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
1448,7,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1448,8,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1448,9,Hepatic cytolysis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1448,10,Hydrops foetalis,Foetal complications NEC,Foetal complications,Preg,N
1448,11,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
1448,12,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1448,13,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
1448,14,Trisomy 18,Autosomal chromosomal abnormalities,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
1448,15,Ultrasound antenatal screen,Foetal and neonatal imaging procedures,Foetal and neonatal investigations,Inv,N
1449,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1449,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1449,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1449,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1450,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1451,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1452,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
1452,2,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1452,3,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1452,4,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1452,5,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
1452,6,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
1453,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1453,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1454,1,Infusion site swelling,Infusion site reactions,Administration site reactions,Genrl,N
1455,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1455,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1456,1,Disorientation,Confusion and disorientation,Deliria (incl confusion),Psych,N
1456,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1456,3,Feeling drunk,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1456,4,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
1457,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1458,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1459,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1459,2,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
1459,3,Disturbance in social behaviour,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
1459,4,Headache,Headaches NEC,Headaches,Nerv,N
1459,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1460,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1460,2,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1460,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1460,4,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1460,5,Suspected product tampering,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1461,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1461,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1461,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1462,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1462,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1462,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1462,4,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
1463,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1463,2,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
1463,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1463,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1464,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1464,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1464,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1464,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1465,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1466,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1466,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1466,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1467,1,Vasculitis,Vasculitides NEC,Vascular infections and inflammations,Vasc,N
1468,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1469,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1469,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1469,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1470,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1470,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1470,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1471,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1471,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1472,1,Cerebral small vessel ischaemic disease,Central nervous system vascular disorders NEC,Central nervous system vascular disorders,Nerv,N
1472,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1472,3,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1472,4,Lacunar infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1473,1,Hepatic cancer,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
1474,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1474,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1475,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1476,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1477,1,Diabetic ketosis,Diabetic complications NEC,Diabetic complications,Metab,N
1477,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1477,3,Sinusitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
1478,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1478,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1478,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1479,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1480,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1480,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1480,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1481,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1482,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1483,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1483,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1483,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1483,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1484,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1484,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1485,1,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1486,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1486,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1486,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1487,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1487,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1487,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1488,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1489,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1489,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1490,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1490,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1490,3,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1491,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1491,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1492,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1492,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1492,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1492,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1493,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1493,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1493,3,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1494,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1494,2,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1494,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1495,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1495,2,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
1495,3,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1496,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1497,1,Gout,Disorders of purine metabolism,Purine and pyrimidine metabolism disorders,Metab,N
1497,2,Hepatic cirrhosis,Hepatic fibrosis and cirrhosis,Hepatic and hepatobiliary disorders,Hepat,N
1497,3,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1497,4,Portal hypertensive gastropathy,Gastric and oesophageal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1497,5,Varices oesophageal,Oesophageal varices,Gastrointestinal vascular conditions,Gastr,N
1498,1,Hip surgery,Joint therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
1499,1,Aortic stenosis,Aortic necrosis and vascular insufficiency,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
1499,2,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
1500,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1501,1,Pernicious anaemia,Anaemia deficiencies,Anaemias nonhaemolytic and marrow depression,Blood,N
1501,2,Vitamin B12 deficiency,Water soluble vitamin deficiencies,Vitamin related disorders,Metab,N
1502,1,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
1502,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1502,3,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
1502,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1502,5,Mass,Mass conditions NEC,Tissue disorders NEC,Genrl,N
1502,6,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1502,7,Skin induration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1503,1,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1504,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1504,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1504,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1504,4,Tonsillar hypertrophy,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
1505,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1505,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1506,1,Device failure,Device issues NEC,Device issues,Prod,N
1506,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
1506,3,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
1507,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1507,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1508,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1508,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1508,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1508,4,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
1509,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1509,2,Product prescribing issue,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1510,1,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1510,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1511,1,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
1511,2,Device failure,Device issues NEC,Device issues,Prod,N
1511,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1511,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1511,5,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1512,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1512,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1512,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1513,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1513,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1514,1,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
1515,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1515,2,Device failure,Device issues NEC,Device issues,Prod,N
1515,3,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
1516,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1516,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1516,3,Device defective,Device physical property and chemical issues,Device issues,Prod,N
1516,4,Device failure,Device issues NEC,Device issues,Prod,N
1516,5,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1517,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1517,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1517,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1518,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
1519,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1519,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1519,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1520,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1520,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1521,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1521,2,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1522,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1522,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1523,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
1523,2,Genital swelling,Reproductive tract signs and symptoms NEC,Reproductive tract disorders NEC,Repro,N
1523,3,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
1523,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1523,5,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
1523,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1524,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1525,1,Congenital bladder anomaly,Bladder disorders congenital,Renal and urinary tract disorders congenital,Cong,N
1525,2,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1525,3,Foetal hypokinesia,Foetal complications NEC,Foetal complications,Preg,N
1525,4,Genitalia external ambiguous,Reproductive tract disorders congenital NEC,Reproductive tract and breast disorders congenital,Cong,N
1525,5,Neonatal respiratory depression,Neonatal hypoxic conditions,Neonatal respiratory disorders,Resp,N
1526,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1526,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1526,3,Inguinal hernia,Inguinal hernias,Abdominal hernias and other abdominal wall conditions,Gastr,N
1526,4,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
1527,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
1527,2,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1527,3,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
1527,4,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
1527,5,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
1527,6,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,Y
1527,7,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1527,8,Urinary incontinence,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
1528,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1529,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1530,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1530,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1531,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
1531,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1531,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
1532,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1532,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1533,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1533,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1533,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1534,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1534,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1535,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1535,2,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1535,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1535,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1536,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1536,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1536,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1536,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1536,5,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1537,1,Arrhythmia neonatal,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
1537,2,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1537,3,Foetal growth restriction,Foetal growth complications,Foetal complications,Preg,N
1537,4,Jaundice neonatal,Neonatal hepatobiliary disorders,Neonatal and perinatal conditions,Preg,N
1537,5,Necrotising enterocolitis neonatal,Gastrointestinal inflammatory disorders NEC,Gastrointestinal inflammatory conditions,Gastr,N
1537,6,Neonatal respiratory distress syndrome,Neonatal hypoxic conditions,Neonatal respiratory disorders,Resp,N
1537,7,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
1538,1,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1539,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1540,1,Accidental exposure to product by child,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
1540,2,Injury,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1541,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1541,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1541,3,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1542,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1542,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1542,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1543,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1543,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1544,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
1544,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
1544,3,Headache,Headaches NEC,Headaches,Nerv,N
1544,4,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1545,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1545,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1545,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1545,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1546,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1546,2,Device failure,Device issues NEC,Device issues,Prod,N
1547,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1547,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1547,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1548,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1548,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1548,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1549,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1549,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1549,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1550,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1550,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1550,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1550,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1551,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1551,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1552,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1552,2,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1553,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1553,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1554,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1554,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1554,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1555,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1555,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1555,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1556,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1557,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1557,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
1557,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1557,4,Lower limb fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
1557,5,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1558,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
1558,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1559,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1559,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1559,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1559,4,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1560,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1560,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1561,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1561,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1561,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1561,4,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1561,5,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1561,6,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1562,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1562,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1562,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1562,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1562,5,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1563,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1563,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1563,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1564,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1564,2,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
1564,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1564,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1564,5,Serum ferritin decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
1565,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1565,2,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1565,3,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1565,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1566,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1566,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1566,3,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1566,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1566,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1567,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1567,2,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
1568,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1568,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1568,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1568,4,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1568,5,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1568,6,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1568,7,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
1569,1,Cystic fibrosis,Pulmonary and bronchial disorders congenital,Respiratory disorders congenital,Cong,Y
1570,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1570,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1570,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1571,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
1572,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1572,2,Guillain-Barre syndrome,Acute polyneuropathies,Peripheral neuropathies,Nerv,N
1572,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1573,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1573,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1573,3,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1573,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1573,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1574,1,Carpal tunnel syndrome,Mononeuropathies,Peripheral neuropathies,Nerv,N
1575,1,Brain injury,Structural brain disorders NEC,Structural brain disorders,Nerv,N
1575,2,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
1575,3,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1575,4,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1575,5,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1575,6,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1576,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1576,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1576,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1577,1,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1578,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1579,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1580,1,Diabetic complication,Diabetic complications NEC,Diabetic complications,Metab,N
1581,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1582,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1582,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1583,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1583,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1583,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1584,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1584,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1584,3,Suicide attempt,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
1585,1,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1586,1,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1587,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1587,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1587,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1587,4,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
1588,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1589,1,Device defective,Device physical property and chemical issues,Device issues,Prod,N
1589,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1589,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1590,1,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
1590,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1590,3,Therapeutic product effect delayed,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1591,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1591,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1591,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1591,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1591,5,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1592,1,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1593,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1594,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1595,1,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1595,2,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1595,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1596,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1596,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1596,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1597,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1597,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1597,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1597,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1597,5,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
1598,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1598,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1599,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1599,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1600,1,Hyperglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1600,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1600,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1601,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1601,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1601,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1601,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1601,5,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1602,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1603,1,Acne,Acnes,Skin appendage conditions,Skin,N
1603,2,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1603,3,Cystitis,Urinary tract infections,Infections - pathogen unspecified,Infec,N
1603,4,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1603,5,Skin papilloma,Skin neoplasms benign,Cutaneous neoplasms benign,Neopl,N
1604,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1604,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1604,3,Head discomfort,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1604,4,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
1604,5,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1605,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1605,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1605,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1606,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1606,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1606,3,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1606,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1606,5,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1607,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1607,2,Chromaturia,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
1607,3,Cold sweat,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1607,4,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
1607,5,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
1607,6,Feeling of body temperature change,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1607,7,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1607,8,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1607,9,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
1607,10,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1607,11,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1607,12,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1607,13,Restlessness,Increased physical activity levels,Changes in physical activity,Psych,N
1608,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1608,2,Device failure,Device issues NEC,Device issues,Prod,N
1608,3,Device issue,Device issues NEC,Device issues,Prod,N
1609,1,Leukaemia,Leukaemias NEC,Leukaemias,Neopl,N
1609,2,Lung neoplasm malignant,Respiratory tract and pleural neoplasms malignant cell type unspecified NEC,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
1610,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1610,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1610,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1610,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1611,1,Device failure,Device issues NEC,Device issues,Prod,N
1611,2,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
1612,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1612,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1613,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1613,2,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1614,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
1614,2,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
1614,3,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
1615,1,Localised infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1616,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1617,1,Abortion missed,Abortions not specified as induced or spontaneous,Abortions and stillbirth,Preg,N
1617,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1618,1,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1618,2,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
1619,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1619,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1620,1,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
1621,1,Device failure,Device issues NEC,Device issues,Prod,N
1621,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1622,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
1622,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1622,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1623,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1623,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1623,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1623,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1624,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1625,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1625,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1626,1,Bladder cancer,Bladder neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
1627,1,Leukaemia,Leukaemias NEC,Leukaemias,Neopl,N
1628,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1628,2,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1628,3,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
1628,4,Presyncope,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1629,1,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1629,2,Diabetic neuropathy,Chronic polyneuropathies,Peripheral neuropathies,Nerv,N
1629,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1629,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1630,1,Cholecystitis infective,Hepatobiliary and spleen infections,Infections - pathogen unspecified,Infec,N
1631,1,Cystitis,Urinary tract infections,Infections - pathogen unspecified,Infec,N
1631,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1631,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1632,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1633,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1633,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1634,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
1634,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1635,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1635,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1635,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1636,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
1636,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1637,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1637,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1637,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1638,1,Infusion site pain,Infusion site reactions,Administration site reactions,Genrl,N
1639,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1639,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1639,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1640,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1640,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1640,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1641,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1641,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1641,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1642,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
1642,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
1643,1,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
1644,1,Localised infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1645,1,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
1646,1,Waldenstrom's macroglobulinaemia,Waldenstrom's macroglobulinaemias,Lymphomas non-Hodgkin's B-cell,Neopl,N
1647,1,Oesophageal carcinoma,Oesophageal neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1648,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1648,2,Catheter site pain,Implant and catheter site reactions,Administration site reactions,Genrl,N
1648,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1648,4,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1648,5,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1649,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
1649,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1649,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1650,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1650,2,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
1650,3,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
1650,4,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1650,5,Product label confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1650,6,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1651,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1651,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1651,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1651,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1652,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1652,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1652,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1653,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1653,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1654,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1654,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1655,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1655,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1656,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1656,2,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
1656,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1656,4,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
1657,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1657,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1658,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1658,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1659,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1659,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1660,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1660,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1660,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1661,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1662,1,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1663,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1663,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1663,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1664,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1665,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1665,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1666,1,Gastrointestinal carcinoma,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1667,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1667,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1668,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1669,1,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1669,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1670,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
1671,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1671,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1671,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1672,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
1672,2,Headache,Headaches NEC,Headaches,Nerv,N
1672,3,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1672,4,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
1672,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1672,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1672,7,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
1672,8,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
1672,9,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
1673,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1673,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1674,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1674,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1674,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1674,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1674,5,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
1675,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1675,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1675,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1675,4,Head injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
1676,1,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
1677,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
1677,2,Troponin increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
1677,3,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
1678,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1678,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1678,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1679,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1679,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1680,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1680,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1680,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1681,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1681,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1682,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
1682,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1682,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1683,1,Coronary artery disease,Coronary artery disorders NEC,Coronary artery disorders,Card,N
1684,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1684,2,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
1685,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1685,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1685,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1686,1,Ichthyosis,Skin and subcutaneous tissue disorders congenital NEC,Skin and subcutaneous tissue disorders congenital,Cong,N
1686,2,Injection site discolouration,Injection site reactions,Administration site reactions,Genrl,N
1686,3,Lipodystrophy acquired,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
1686,4,Skin hypertrophy,Skin hyperplasias and hypertrophies,Cornification and dystrophic skin disorders,Skin,N
1686,5,Skin plaque,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1687,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1687,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1688,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1689,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1689,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1689,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1690,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
1690,2,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
1691,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1691,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1691,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1692,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1692,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1692,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1692,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1692,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1692,6,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1692,7,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1692,8,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1692,9,Urine ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1692,10,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1693,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1693,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1693,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1693,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1694,1,Device defective,Device physical property and chemical issues,Device issues,Prod,N
1694,2,Device issue,Device issues NEC,Device issues,Prod,N
1694,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1695,1,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
1696,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
1696,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1696,3,Headache,Headaches NEC,Headaches,Nerv,N
1696,4,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1696,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1697,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1698,1,Device failure,Device issues NEC,Device issues,Prod,N
1698,2,Organ failure,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1699,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
1699,2,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1700,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1700,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1700,3,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
1701,1,Migraine,Migraine headaches,Headaches,Nerv,N
1702,1,Infusion site infection,Vascular infections,Infections - pathogen unspecified,Infec,N
1702,2,Infusion site rash,Infusion site reactions,Administration site reactions,Genrl,N
1702,3,Infusion site urticaria,Infusion site reactions,Administration site reactions,Genrl,N
1703,1,Age-related macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
1703,2,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
1704,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
1704,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1704,3,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1704,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1704,5,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1705,1,Coeliac disease,Malabsorption syndromes,Malabsorption conditions,Gastr,N
1706,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
1707,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1708,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1709,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1709,2,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
1709,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1709,4,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1710,1,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
1710,2,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1710,3,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
1710,4,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1710,5,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1710,6,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
1711,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1712,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1712,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1712,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1712,4,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
1712,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1712,6,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1712,7,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1712,8,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1713,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1713,2,Delirium,Deliria,Deliria (incl confusion),Psych,N
1713,3,Knee operation,Joint therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
1713,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1714,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1714,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1714,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1715,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1715,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1716,1,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1717,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1717,2,Vertigo positional,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
1718,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1718,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1718,3,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1718,4,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1718,5,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1718,6,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1718,7,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
1718,8,Hypophagia,Appetite disorders,Appetite and general nutritional disorders,Metab,N
1718,9,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1718,10,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
1718,11,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
1719,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1719,2,Gastroenteritis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
1720,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1720,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1720,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
1721,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1722,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
1722,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1723,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
1723,2,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1723,3,Skin hypertrophy,Skin hyperplasias and hypertrophies,Cornification and dystrophic skin disorders,Skin,N
1723,4,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1724,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1724,2,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
1725,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
1726,1,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
1726,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1726,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1726,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1727,1,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1727,2,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
1727,3,Diabetic neuropathy,Chronic polyneuropathies,Peripheral neuropathies,Nerv,N
1727,4,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
1727,5,End stage renal disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1727,6,Squamous cell carcinoma of skin,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
1728,1,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
1729,1,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1729,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1729,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1730,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1730,2,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1730,3,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1730,4,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1731,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1731,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
1732,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1732,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1732,3,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1732,4,Road traffic accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1733,1,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1734,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1734,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1735,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1735,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1736,1,Degenerative aortic valve disease,Aortic valvular disorders,Cardiac valve disorders,Card,N
1737,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1737,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1737,3,Injection site discomfort,Injection site reactions,Administration site reactions,Genrl,N
1737,4,Knee operation,Joint therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
1737,5,Lack of injection site rotation,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1737,6,Limb operation,Limb therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
1738,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1738,2,Heart valve incompetence,Cardiac valve disorders NEC,Cardiac valve disorders,Card,N
1739,1,Aortic stenosis,Aortic necrosis and vascular insufficiency,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
1739,2,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1739,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1739,4,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1739,5,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1739,6,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1740,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1740,2,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
1740,3,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1740,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1740,5,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1741,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1742,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1742,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1743,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
1743,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1744,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1745,1,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1746,1,Uterine cancer,Uterine neoplasms malignant NEC,Reproductive neoplasms female malignant and unspecified,Neopl,N
1747,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1748,1,Prostatic abscess,Male reproductive tract infections,Infections - pathogen unspecified,Infec,N
1749,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1749,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1750,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1750,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1750,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1751,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1751,2,Diabetic nephropathy,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
1751,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1751,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1751,5,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1752,1,Hepatic cancer,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
1753,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1753,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1753,3,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1753,4,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
1753,5,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
1753,6,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1753,7,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1754,1,Coma,Coma states,Neurological disorders NEC,Nerv,N
1754,2,Product communication issue,Product transcribing errors and communication issues,Medication errors and other product use errors and issues,Inj&P,N
1755,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1756,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1756,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1756,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1757,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1758,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1758,2,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
1758,3,Vascular rupture,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
1759,1,Device defective,Device physical property and chemical issues,Device issues,Prod,N
1759,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1760,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
1760,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1760,3,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1761,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
1762,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1762,2,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1762,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1763,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1763,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1764,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1764,2,Device defective,Device physical property and chemical issues,Device issues,Prod,N
1764,3,Device leakage,Device issues NEC,Device issues,Prod,N
1764,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1764,5,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1764,6,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1765,1,Renal neoplasm,Urinary tract neoplasms unspecified malignancy NEC,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
1766,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
1767,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1767,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1767,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1767,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1767,5,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1768,1,Localised infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1769,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1769,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1769,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1769,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1770,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1770,2,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1771,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1771,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1772,1,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1773,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
1774,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1775,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1776,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1776,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1776,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1776,4,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1777,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1777,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1777,3,Device defective,Device physical property and chemical issues,Device issues,Prod,N
1777,4,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
1777,5,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1777,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1777,7,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1777,8,Therapeutic product effect variable,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1778,1,Chronic lymphocytic leukaemia,Leukaemias chronic lymphocytic,Leukaemias,Neopl,N
1779,1,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
1779,2,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1780,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1781,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1781,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1781,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1781,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1781,5,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1781,6,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1781,7,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1781,8,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1782,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1783,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1783,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1783,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1783,4,Suspected COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1784,1,Bladder cancer,Bladder neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
1785,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1785,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1786,1,Benign prostatic hyperplasia,Prostatic neoplasms and hypertrophy,Prostatic disorders (excl infections and inflammations),Repro,N
1786,2,Umbilical hernia,Umbilical hernias,Abdominal hernias and other abdominal wall conditions,Gastr,N
1787,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1788,1,Cataract operation,Lens therapeutic procedures,Eye therapeutic procedures,Surg,N
1789,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1789,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1789,3,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
1789,4,Device dislocation,Device issues NEC,Device issues,Prod,N
1789,5,Expired device used,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1789,6,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1790,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1790,2,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1791,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1791,2,Exposure via breast milk,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1791,3,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1792,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1792,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1793,1,Diabetic ketoacidotic hyperglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
1794,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1795,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1795,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1796,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1796,2,Device defective,Device physical property and chemical issues,Device issues,Prod,N
1796,3,Device occlusion,Device malfunction events NEC,Device issues,Prod,N
1796,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1796,5,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1796,6,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1796,7,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
1797,1,COVID-19 pneumonia,Coronavirus infections,Viral infectious disorders,Infec,N
1797,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1798,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1798,2,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
1799,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1799,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1799,3,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
1799,4,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
1800,1,Coronary artery bypass,Arterial therapeutic procedures (excl aortic),Vascular therapeutic procedures,Surg,N
1800,2,Heart valve operation,Cardiac valve therapeutic procedures,Cardiac therapeutic procedures,Surg,N
1800,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
1801,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1801,2,Lack of infusion site rotation,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1801,3,Malabsorption from administration site,Administration site reactions NEC,Administration site reactions,Genrl,N
1802,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1802,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1802,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1802,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1803,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1804,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1805,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1805,2,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1805,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1805,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1805,5,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1806,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
1806,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1807,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1807,2,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1808,1,Bladder cancer,Bladder neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
1809,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1809,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1810,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
1811,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1811,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1811,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1811,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1811,5,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1811,6,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1811,7,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1812,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1812,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1813,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1814,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1814,2,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1815,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
1816,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
1817,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1818,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1819,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1819,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1820,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1820,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1821,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1822,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1822,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1822,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1822,4,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1822,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1822,6,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1822,7,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
1822,8,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
1822,9,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1822,10,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
1823,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1823,2,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1824,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1825,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1826,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1826,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1827,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
1828,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
1828,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
1828,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
1828,4,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
1828,5,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
1829,1,Gastrointestinal carcinoma,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
1830,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
1830,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
1830,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
1831,1,Device failure,Device issues NEC,Device issues,Prod,N
1831,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1832,1,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
1833,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1834,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1834,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1834,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1835,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1835,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1836,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1837,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1837,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1838,1,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1838,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1838,3,Infusion site mass,Infusion site reactions,Administration site reactions,Genrl,N
1838,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1838,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1839,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1839,2,Disorientation,Confusion and disorientation,Deliria (incl confusion),Psych,N
1839,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1839,4,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1839,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1840,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
1840,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1840,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1840,4,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1840,5,Sneezing,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
1841,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
1842,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1842,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1843,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1843,2,Toe amputation,Limb therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
1844,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1844,2,End stage renal disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
1845,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1846,1,Cyanosis,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
1846,2,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1846,3,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
1846,4,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
1847,1,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1847,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1847,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1847,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1848,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1848,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1848,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1849,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1849,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1850,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1851,1,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1851,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1852,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1852,2,Intraventricular haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1853,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1854,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1854,2,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
1855,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1856,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
1856,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1856,3,Lipodystrophy acquired,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
1856,4,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1857,1,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1857,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1857,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1858,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1859,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1859,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1860,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1860,2,Malabsorption from injection site,Injection site reactions,Administration site reactions,Genrl,N
1861,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1861,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1861,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1861,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1861,5,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1861,6,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1862,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1862,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1862,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1863,1,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
1863,2,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1864,1,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
1864,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
1864,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1865,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1865,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1865,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1865,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1866,1,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
1866,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
1866,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1867,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1867,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1868,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1868,2,Hypoglycaemia neonatal,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1869,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1869,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1869,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1869,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1870,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1870,2,Device failure,Device issues NEC,Device issues,Prod,N
1871,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1871,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1871,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1872,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1873,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
1873,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1873,3,Bone debridement,Bone therapeutic procedures NEC,Bone and joint therapeutic procedures,Surg,N
1873,4,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
1873,5,Diabetic gastroparesis,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
1873,6,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
1873,7,Tendonitis,Tendon disorders,"Tendon, ligament and cartilage disorders",Musc,N
1874,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1874,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1875,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1875,2,Device delivery system issue,Device issues NEC,Device issues,Prod,N
1875,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1875,4,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
1876,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1876,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1876,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1876,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1877,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1878,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1878,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1878,3,Hypoglycaemic unconsciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
1878,4,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
1879,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1879,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1880,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1880,2,Therapeutic response shortened,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1881,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1881,2,Product packaging issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1881,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1881,4,Product temperature excursion issue,Product distribution and storage issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1882,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1882,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1883,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1884,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1884,2,Device information output issue,Device information output issues,Device issues,Prod,N
1884,3,Device power source issue,Device malfunction events NEC,Device issues,Prod,N
1884,4,Expired device used,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1884,5,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1884,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1885,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1885,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1885,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1885,4,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
1886,1,Heart rate abnormal,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
1887,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1888,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1889,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1889,2,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1889,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1889,4,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
1889,5,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1890,1,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1890,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1891,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1892,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1892,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1892,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1892,4,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1892,5,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1892,6,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1892,7,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
1893,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1894,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1895,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1895,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1896,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1897,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1897,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1898,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1899,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1900,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1901,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1902,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1902,2,Device issue,Device issues NEC,Device issues,Prod,N
1902,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1902,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1903,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1904,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1904,2,Headache,Headaches NEC,Headaches,Nerv,N
1904,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1905,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1905,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1905,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
1906,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1906,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1907,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1907,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1907,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1908,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1908,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1908,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1908,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1909,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1909,2,Device defective,Device physical property and chemical issues,Device issues,Prod,N
1909,3,Device failure,Device issues NEC,Device issues,Prod,N
1909,4,Injection site discolouration,Injection site reactions,Administration site reactions,Genrl,N
1909,5,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1909,6,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
1910,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1910,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1910,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1910,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1911,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1911,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1912,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1912,2,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1912,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1912,4,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
1913,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
1913,2,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
1913,3,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1913,4,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1913,5,Hepatic steatosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
1914,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1914,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1915,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1915,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1915,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1916,1,Glycosylated haemoglobin decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1916,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1917,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1917,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
1917,3,Device mechanical issue,Device physical property and chemical issues,Device issues,Prod,N
1917,4,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1917,5,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
1918,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1919,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1919,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1919,3,Stress,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
1920,1,Allergy to vaccine,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1920,2,Respiratory disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
1921,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
1921,2,Injection site scar,Injection site reactions,Administration site reactions,Genrl,N
1922,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1922,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1922,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1923,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1923,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1923,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1924,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1924,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1924,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1925,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1925,2,Device failure,Device issues NEC,Device issues,Prod,N
1926,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1926,2,Device physical property issue,Device physical property and chemical issues,Device issues,Prod,N
1927,1,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
1928,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
1929,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1930,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1930,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1930,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1931,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
1932,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1932,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1933,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1933,2,Infusion site inflammation,Infusion site reactions,Administration site reactions,Genrl,N
1933,3,Malabsorption from injection site,Injection site reactions,Administration site reactions,Genrl,N
1934,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1934,2,Injection site injury,Injection site reactions,Administration site reactions,Genrl,N
1935,1,Nephrotic syndrome,Glomerulonephritis and nephrotic syndrome,Nephropathies,Renal,N
1936,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1936,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1936,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1937,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1938,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1938,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1938,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1939,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1939,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
1940,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1940,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1940,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1941,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1941,2,Device ineffective,Device issues NEC,Device issues,Prod,N
1941,3,Device issue,Device issues NEC,Device issues,Prod,N
1941,4,Incorrect dose administered by product,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1942,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1942,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1943,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
1943,2,Euphoric mood,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
1943,3,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1943,4,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1943,5,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1943,6,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1943,7,Quality of life decreased,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
1943,8,Vomiting projectile,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
1944,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1944,2,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1945,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
1946,1,Glycosylated haemoglobin abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1946,2,Hypoglycaemia unawareness,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1947,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1948,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1948,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1949,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1950,1,Prostate cancer,Prostatic neoplasms malignant,Reproductive neoplasms male malignant and unspecified,Neopl,N
1951,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1951,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1952,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1952,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1953,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
1953,2,Product package associated injury,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1953,3,Wound,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
1954,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1955,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1955,2,Device failure,Device issues NEC,Device issues,Prod,N
1955,3,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
1956,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1957,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
1958,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1958,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1959,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
1959,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
1959,3,Functional gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
1959,4,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
1959,5,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
1959,6,Sneezing,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
1959,7,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
1959,8,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
1960,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1960,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1961,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1962,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1962,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1962,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1962,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1963,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1963,2,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
1964,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1964,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1965,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
1966,1,Neoplasm,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
1967,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1967,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1967,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1968,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1968,2,Product packaging quantity issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1968,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1969,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1969,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1970,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1970,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
1971,1,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
1971,2,Self-injurious ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
1972,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
1973,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1974,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1974,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1975,1,Dose calculation error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1975,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1976,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1976,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1976,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1977,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1977,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1977,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1978,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1978,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1978,3,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1978,4,Ketosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
1979,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1979,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1979,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1979,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1980,1,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
1981,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1982,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1982,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1982,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
1983,1,Lipodystrophy acquired,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
1984,1,Pleurisy,Pleural infections and inflammations,Pleural disorders,Resp,N
1984,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
1985,1,Ankle fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
1986,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1987,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1987,2,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1988,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1988,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1989,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1989,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1989,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1990,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1991,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1991,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
1992,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1992,2,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
1993,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1994,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1994,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
1995,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1995,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1996,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1997,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1997,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
1998,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
1998,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
1999,1,Drug tolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1999,2,Therapeutic product effect delayed,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2000,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2000,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2000,3,Gastric bypass,Gastric therapeutic procedures,Gastrointestinal therapeutic procedures,Surg,N
2000,4,Therapeutic product effect delayed,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2000,5,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
2001,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2001,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2002,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2002,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
2002,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2003,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2003,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2004,1,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
2004,2,Macular hole,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
2005,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
2006,1,Infusion site abscess,Vascular infections,Infections - pathogen unspecified,Infec,N
2007,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2007,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2007,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2008,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2008,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
2008,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2008,4,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
2009,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2009,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2010,1,Adenocarcinoma of colon,Colorectal neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
2011,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2012,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2013,1,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
2013,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2014,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2015,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2015,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2016,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2016,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2017,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2017,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2018,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2018,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2018,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2019,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2020,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2021,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2021,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2021,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2022,1,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
2023,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2024,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
2024,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
2024,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2024,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2024,5,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
2024,6,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
2024,7,Stress,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
2025,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2025,2,Cardiac assistance device user,Disability issues,Lifestyle issues,SocCi,N
2026,1,Generalised oedema,Oedema NEC,General system disorders NEC,Genrl,N
2027,1,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
2028,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2028,2,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
2028,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2028,4,Paralysis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
2029,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
2030,1,Device leakage,Device issues NEC,Device issues,Prod,N
2030,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2030,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2031,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2032,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
2032,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2032,3,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
2032,4,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2033,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2034,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2034,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2034,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2034,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2035,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2035,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2035,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2036,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2036,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2036,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2037,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2038,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2038,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2039,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2039,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2040,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
2040,2,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
2040,3,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2040,4,Product prescribing issue,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2041,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2042,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2042,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2042,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2043,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2044,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2045,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2046,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2047,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2048,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2048,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2048,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2049,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2049,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2050,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2051,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2051,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2051,3,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2052,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2053,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2054,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2054,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2054,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2055,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
2056,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2056,2,Device defective,Device physical property and chemical issues,Device issues,Prod,N
2056,3,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
2056,4,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
2057,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2057,2,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
2057,3,Tonsillitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
2058,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2058,2,Infusion site bruising,Infusion site reactions,Administration site reactions,Genrl,N
2059,1,Gastroenteritis viral,Viral infections NEC,Viral infectious disorders,Infec,N
2060,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2060,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2060,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2060,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2061,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
2061,2,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
2062,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2062,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2063,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2063,2,Euglycaemic diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2063,3,Metabolic acidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
2063,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2063,5,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
2063,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
2064,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2064,2,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
2064,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2065,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2065,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2066,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
2067,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2067,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2068,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
2069,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2070,1,Acetonaemia,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
2070,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2071,1,Infusion site infection,Vascular infections,Infections - pathogen unspecified,Infec,N
2072,1,Drug effect faster than expected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2072,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2073,1,Supraventricular tachycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
2074,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2074,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2074,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2075,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2075,2,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2075,3,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
2075,4,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
2075,5,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
2075,6,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
2075,7,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2075,8,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2075,9,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2075,10,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2075,11,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
2075,12,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2075,13,Headache,Headaches NEC,Headaches,Nerv,N
2075,14,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2075,15,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2075,16,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
2075,17,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2075,18,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2076,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2077,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
2077,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2077,3,Food craving,Appetite disorders,Appetite and general nutritional disorders,Metab,N
2078,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2078,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2079,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
2079,2,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
2080,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
2080,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2081,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2081,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
2081,3,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
2082,1,Prostate cancer,Prostatic neoplasms malignant,Reproductive neoplasms male malignant and unspecified,Neopl,N
2083,1,Device defective,Device physical property and chemical issues,Device issues,Prod,N
2083,2,Device issue,Device issues NEC,Device issues,Prod,N
2083,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2083,4,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2084,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2084,2,Increased insulin requirement,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2085,1,Nerve compression,Mononeuropathies,Peripheral neuropathies,Nerv,N
2086,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2086,2,Infusion site inflammation,Infusion site reactions,Administration site reactions,Genrl,N
2086,3,Lack of infusion site rotation,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2087,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2087,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2087,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2088,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2088,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2088,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2089,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2089,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2090,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2091,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2091,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2091,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2092,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2092,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2093,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2094,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2094,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2095,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2095,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2096,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2097,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2097,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
2097,3,Device failure,Device issues NEC,Device issues,Prod,N
2097,4,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
2098,1,Device information output issue,Device information output issues,Device issues,Prod,N
2098,2,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2098,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2099,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2099,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2099,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2099,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2099,5,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2100,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2101,1,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
2102,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2103,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2103,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2104,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2104,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
2104,3,Device information output issue,Device information output issues,Device issues,Prod,N
2104,4,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2104,5,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2104,6,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2105,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2105,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2105,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2106,1,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
2107,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2108,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2109,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2109,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2110,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
2111,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2111,2,Device infusion issue,Device malfunction events NEC,Device issues,Prod,N
2111,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2111,4,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2111,5,Inappropriate schedule of product discontinuation,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2112,1,Deformity,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2112,2,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
2112,3,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
2113,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2113,2,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
2114,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2115,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2115,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2116,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2116,2,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
2116,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2116,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2116,5,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2117,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2118,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2118,2,Device occlusion,Device malfunction events NEC,Device issues,Prod,N
2118,3,Drug delivery system issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2118,4,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2118,5,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
2119,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
2120,1,Diabetic ketoacidotic hyperglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
2121,1,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
2122,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2122,2,Device information output issue,Device information output issues,Device issues,Prod,N
2122,3,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
2122,4,Device mechanical issue,Device physical property and chemical issues,Device issues,Prod,N
2122,5,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2122,6,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
2123,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2123,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2123,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2124,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
2125,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2125,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2126,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2126,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2126,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2127,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2127,2,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
2128,1,Retinal tear,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
2129,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2130,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2130,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2131,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2131,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2131,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2132,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2132,2,Device failure,Device issues NEC,Device issues,Prod,N
2132,3,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
2132,4,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
2133,1,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
2134,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2134,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2134,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2135,1,Gastrointestinal carcinoma,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
2136,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2136,2,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2136,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2136,4,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2136,5,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2136,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2136,7,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2136,8,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
2136,9,Renal pain,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
2137,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2137,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
2138,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2139,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2139,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2140,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2140,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2140,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2140,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2140,5,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2141,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
2142,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2142,2,Device failure,Device issues NEC,Device issues,Prod,N
2143,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2143,2,Suspected product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2144,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2145,1,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2145,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2146,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2146,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
2146,3,Device failure,Device issues NEC,Device issues,Prod,N
2146,4,Expired device used,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2147,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
2148,1,Addison's disease,Adrenal cortical hypofunctions,Adrenal gland disorders,Endo,N
2148,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2148,3,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2148,4,Ketosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
2149,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2150,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2150,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2151,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2152,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2152,2,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2152,3,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
2153,1,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2153,2,Vasodilatation,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
2154,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2155,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2155,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2156,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2156,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2156,3,Grief reaction,Adjustment disorders,Adjustment disorders (incl subtypes),Psych,N
2156,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2156,5,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2157,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2158,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
2158,2,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
2158,3,COVID-19 pneumonia,Coronavirus infections,Viral infectious disorders,Infec,N
2158,4,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
2158,5,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
2158,6,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
2158,7,Streptococcal sepsis,Streptococcal infections,Bacterial infectious disorders,Infec,N
2159,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2159,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
2160,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2160,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
2160,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2160,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2160,5,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2161,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2161,2,Device deployment issue,Device malfunction events NEC,Device issues,Prod,N
2161,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2161,4,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
2162,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2162,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2162,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2163,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2163,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2164,1,Foetal distress syndrome,Foetal complications NEC,Foetal complications,Preg,N
2165,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2165,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2166,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2166,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2167,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
2168,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2169,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2169,2,Device failure,Device issues NEC,Device issues,Prod,N
2170,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2170,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2170,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2171,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2171,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
2172,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2173,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
2174,1,Caesarean section,Obstetric therapeutic procedures,Obstetric and gynaecological therapeutic procedures,Surg,N
2174,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2175,1,Catheter site related reaction,Implant and catheter site reactions,Administration site reactions,Genrl,N
2176,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2176,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2177,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2177,2,Infusion site discharge,Infusion site reactions,Administration site reactions,Genrl,N
2177,3,Infusion site erythema,Infusion site reactions,Administration site reactions,Genrl,N
2177,4,Infusion site irritation,Infusion site reactions,Administration site reactions,Genrl,N
2177,5,Infusion site pruritus,Infusion site reactions,Administration site reactions,Genrl,N
2177,6,Infusion site swelling,Infusion site reactions,Administration site reactions,Genrl,N
2178,1,Non-cardiac chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2179,1,Drug diversion,Criminal activity,Legal issues,SocCi,N
2179,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2180,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
2181,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2181,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
2181,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2182,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2182,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2183,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2183,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2183,3,Product preparation error,Product preparation errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2184,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2184,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2184,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2184,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2184,5,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2184,6,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2185,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2185,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2186,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2186,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2186,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2187,1,Glycosylated haemoglobin abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2188,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2188,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2188,3,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2188,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2188,5,Product odour abnormal,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2188,6,Product packaging quantity issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2188,7,Tooth abscess,Dental and oral soft tissue infections,Infections - pathogen unspecified,Infec,N
2189,1,Blood creatine abnormal,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
2189,2,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2190,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2191,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2191,2,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2192,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2192,2,Infusion site inflammation,Infusion site reactions,Administration site reactions,Genrl,N
2193,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2193,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2194,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
2195,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2195,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2195,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2195,4,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
2196,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
2197,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2197,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2197,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2198,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2198,2,Device failure,Device issues NEC,Device issues,Prod,N
2198,3,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
2198,4,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2198,5,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2199,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2200,1,Prostatic operation,Prostatic therapeutic procedures,Male genital tract therapeutic procedures,Surg,N
2201,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2202,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
2203,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2203,2,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2204,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2204,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
2205,1,Infusion site pain,Infusion site reactions,Administration site reactions,Genrl,N
2206,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2206,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2207,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
2208,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2208,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2208,3,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
2208,4,Surgery,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
2209,1,Affective disorder,Mood disorders NEC,Mood disorders and disturbances NEC,Psych,N
2209,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2210,1,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
2211,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2211,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2212,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2212,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
2212,3,Device failure,Device issues NEC,Device issues,Prod,N
2213,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2214,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2215,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2215,2,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2216,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2216,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2217,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2217,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
2217,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2217,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2217,5,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2217,6,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
2218,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2218,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2219,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2220,1,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
2220,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2220,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2221,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2221,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2222,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2222,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
2222,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2223,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2223,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2224,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2224,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2225,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2225,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2225,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2225,4,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2226,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2226,2,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2226,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2227,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2227,2,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
2227,3,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2227,4,Eye colour change,"Iris and ciliary body structural change, deposit and degeneration","Anterior eye structural change, deposit and degeneration",Eye,N
2227,5,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
2227,6,Headache,Headaches NEC,Headaches,Nerv,N
2227,7,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
2228,1,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
2229,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2230,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
2230,2,Infusion site erythema,Infusion site reactions,Administration site reactions,Genrl,N
2230,3,Infusion site inflammation,Infusion site reactions,Administration site reactions,Genrl,N
2230,4,Infusion site pruritus,Infusion site reactions,Administration site reactions,Genrl,N
2230,5,Infusion site rash,Infusion site reactions,Administration site reactions,Genrl,N
2230,6,Infusion site vesicles,Infusion site reactions,Administration site reactions,Genrl,N
2231,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2231,2,Device defective,Device physical property and chemical issues,Device issues,Prod,N
2231,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2231,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2232,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2233,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2233,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2233,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2234,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
2235,1,Anti-insulin antibody,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
2236,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2237,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
2238,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2238,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2238,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2239,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2240,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2240,2,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
2241,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2241,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2242,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
2243,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2243,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2243,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2244,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2245,1,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
2246,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2247,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2247,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2248,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2249,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2250,1,Appetite disorder,Appetite disorders,Appetite and general nutritional disorders,Metab,N
2250,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2251,1,Heart transplant,Cardiac therapeutic procedures NEC,Cardiac therapeutic procedures,Surg,N
2252,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
2253,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2253,2,Injection site discharge,Injection site reactions,Administration site reactions,Genrl,N
2254,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2254,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2254,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2254,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2255,1,Blood insulin abnormal,"Gastrointestinal, pancreatic and APUD hormone analyses",Endocrine investigations (incl sex hormones),Inv,N
2255,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2255,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
2256,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2257,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2257,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2257,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2258,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2258,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2258,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2259,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2260,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2260,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
2260,3,Device failure,Device issues NEC,Device issues,Prod,N
2261,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2261,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2261,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2261,4,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2261,5,Manufacturing issue,Manufacturing issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2262,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2262,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2263,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
2263,2,Drug dispensed to wrong patient,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2264,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2264,2,Device failure,Device issues NEC,Device issues,Prod,N
2264,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2265,1,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
2265,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2265,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2266,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2266,2,Device failure,Device issues NEC,Device issues,Prod,N
2266,3,Drug delivery system issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2267,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2267,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2268,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2268,2,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2269,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2269,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2269,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2270,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2270,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2270,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2270,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2271,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2272,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2272,2,Increased insulin requirement,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2273,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2273,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2274,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2275,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2275,2,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2275,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2276,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2276,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2276,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2277,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2278,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2278,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2278,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2279,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2280,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2281,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2281,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2282,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
2282,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2282,3,Rheumatoid arthritis,Rheumatoid arthropathies,Joint disorders,Musc,N
2282,4,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2283,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2283,2,Immunoglobulins increased,Immunoglobulin analyses,Immunology and allergy investigations,Inv,N
2283,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2284,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2285,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
2285,2,Drug delivery system issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2285,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2285,4,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2286,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2287,1,SARS-CoV-2 test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
2288,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2288,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2289,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2290,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
2290,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2290,3,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2291,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
2292,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2292,2,Device leakage,Device issues NEC,Device issues,Prod,N
2292,3,Expired device used,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2292,4,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2292,5,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2293,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2293,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2294,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2295,1,Housebound,Disability issues,Lifestyle issues,SocCi,N
2296,1,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2296,2,Product appearance confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2296,3,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2297,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2297,2,Product deposit,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2297,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2298,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2298,2,Product deposit,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2298,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2299,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2299,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2299,3,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
2300,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2300,2,Product deposit,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2300,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2301,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2301,2,Prescription drug used without a prescription,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2301,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2302,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2302,2,Product deposit,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2303,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
2303,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2303,3,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2303,4,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
2304,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2304,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2304,3,Product temperature excursion issue,Product distribution and storage issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2305,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2305,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2305,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2306,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2306,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2307,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
2308,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2308,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2308,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2309,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
2310,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2311,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2311,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2311,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2312,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
2313,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2313,2,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2314,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2314,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2315,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2315,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2315,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2316,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2316,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2317,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2317,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2317,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2317,4,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
2317,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2317,6,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
2318,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2318,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
2318,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2318,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2318,5,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
2319,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2319,2,Device failure,Device issues NEC,Device issues,Prod,N
2319,3,Device issue,Device issues NEC,Device issues,Prod,N
2319,4,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2320,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2321,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2322,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2323,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2323,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2324,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2324,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2325,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2326,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2326,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2327,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2328,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2328,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2329,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2329,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2329,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2330,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2330,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2330,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2331,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2331,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2331,3,Leg amputation,Limb therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
2332,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2332,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2333,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2333,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
2334,1,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
2334,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2334,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2334,4,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2335,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
2335,2,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
2335,3,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
2335,4,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2335,5,Hepatic cytolysis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,Y
2335,6,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
2335,7,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
2336,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2336,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2336,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2336,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2336,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2336,6,Increased insulin requirement,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2337,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2337,2,Road traffic accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2338,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2338,2,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2339,1,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
2339,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
2340,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2340,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2341,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2342,1,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
2342,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2342,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2342,4,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2343,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2343,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2344,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2344,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2345,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2346,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
2346,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
2346,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2347,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2347,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2347,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2348,1,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
2348,2,Injection site discharge,Injection site reactions,Administration site reactions,Genrl,N
2349,1,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
2349,2,Foreign body sensation in eyes,Ocular sensation disorders,Ocular sensory symptoms NEC,Eye,N
2350,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2350,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2351,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
2351,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2351,3,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
2352,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2352,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2352,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2353,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2353,2,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2354,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
2354,2,Pharyngeal swelling,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
2354,3,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2355,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2355,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2356,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2356,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2357,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2357,2,Therapeutic response shortened,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2358,1,Infusion site pain,Infusion site reactions,Administration site reactions,Genrl,N
2359,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2359,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2359,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2359,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2360,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2361,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2361,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2361,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2362,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2362,2,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2363,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
2363,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2364,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2364,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2364,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2364,4,Product preparation error,Product preparation errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2364,5,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2365,1,Heart rate,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
2366,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
2367,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2367,2,Device failure,Device issues NEC,Device issues,Prod,N
2367,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2367,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2368,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2368,2,Headache,Headaches NEC,Headaches,Nerv,N
2368,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2369,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2370,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2370,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2370,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2371,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2371,2,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2372,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2372,2,Product appearance confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2372,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2373,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2373,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2374,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2375,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2375,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2375,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2376,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2376,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2377,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2378,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2378,2,Migraine,Migraine headaches,Headaches,Nerv,N
2378,3,Therapeutic product effect variable,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2379,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2379,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2379,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2380,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2380,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2381,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2381,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
2382,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2383,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2383,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2383,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2383,4,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2383,5,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2383,6,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2383,7,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2383,8,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2383,9,Product packaging quantity issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2384,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2385,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
2385,2,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
2386,1,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
2386,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
2387,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2387,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2387,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2388,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2388,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
2388,3,Product appearance confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2388,4,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2389,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2390,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2391,1,Injection site atrophy,Injection site reactions,Administration site reactions,Genrl,N
2391,2,Muscle atrophy,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
2392,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2392,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2392,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2393,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2393,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2394,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2394,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
2394,3,Device failure,Device issues NEC,Device issues,Prod,N
2395,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2395,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2395,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2395,4,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
2396,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2397,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2398,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
2399,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2399,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2400,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2400,2,Drug effect less than expected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2401,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2402,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
2402,2,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
2402,3,Rhinalgia,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
2402,4,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2403,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
2403,2,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2403,3,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
2404,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2404,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2405,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2405,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2406,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2406,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2407,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
2407,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
2408,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2408,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2409,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2409,2,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
2409,3,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2409,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2410,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2410,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2411,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
2411,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
2411,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2411,4,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2411,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2412,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2412,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2413,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2413,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2414,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2415,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2415,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2415,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2415,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2416,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2416,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2417,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2417,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2418,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2418,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2418,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2419,1,Haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
2419,2,Haemolytic anaemia,Anaemias haemolytic NEC,Haemolyses and related conditions,Blood,N
2419,3,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
2419,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2419,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2419,6,Ocular icterus,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
2420,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2420,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2421,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2421,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2421,3,Device failure,Device issues NEC,Device issues,Prod,N
2421,4,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
2422,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2422,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2422,3,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
2422,4,Urine ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
2423,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2423,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2423,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
2424,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2424,2,Therapeutic product effect delayed,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2425,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
2425,2,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
2425,3,Skin swelling,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2426,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2426,2,Device failure,Device issues NEC,Device issues,Prod,N
2427,1,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
2427,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2427,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2428,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2428,2,Product dose omission in error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2428,3,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2428,4,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2429,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2429,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2429,3,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
2430,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2430,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2430,3,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
2431,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2432,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2432,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
2432,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2433,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2433,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2433,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2434,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2434,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2434,3,Increased insulin requirement,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2434,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2435,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2436,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2436,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2437,1,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
2438,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2438,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2438,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2439,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2440,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
2441,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2442,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2442,2,Device defective,Device physical property and chemical issues,Device issues,Prod,N
2442,3,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
2442,4,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
2442,5,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
2442,6,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2442,7,Nervousness,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
2443,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2443,2,Nervous system disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
2443,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2444,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2444,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2444,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2445,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2446,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2446,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2446,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2446,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2446,5,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2446,6,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2447,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2447,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2448,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2449,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2450,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2450,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2450,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2451,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2451,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
2451,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2451,4,Intentional misuse of drug delivery system,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
2451,5,Product label on wrong product,Product label issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2452,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2453,1,Musculoskeletal stiffness,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
2453,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2454,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2454,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2455,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2456,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
2456,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
2457,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2458,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
2459,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2459,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2460,1,Blood ketone body,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
2460,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2460,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2461,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2462,1,Anaphylactic shock,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
2463,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2463,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2464,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
2465,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2465,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2465,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2465,4,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
2466,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2466,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2466,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2467,1,Device issue,Device issues NEC,Device issues,Prod,N
2467,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
2468,1,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
2468,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
2468,3,Device mechanical issue,Device physical property and chemical issues,Device issues,Prod,N
2468,4,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2468,5,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2469,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2469,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2469,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2470,1,Wrist fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
2471,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2471,2,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
2471,3,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
2471,4,Limb discomfort,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2471,5,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2472,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2472,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2472,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2473,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
2474,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2475,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2476,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2477,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2477,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2478,1,Coeliac disease,Malabsorption syndromes,Malabsorption conditions,Gastr,N
2479,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2479,2,Device failure,Device issues NEC,Device issues,Prod,N
2479,3,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
2480,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2480,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
2480,3,Device mechanical issue,Device physical property and chemical issues,Device issues,Prod,N
2481,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2481,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2481,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2482,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
2482,2,Bronchiectasis,Bronchial conditions NEC,Bronchial disorders (excl neoplasms),Resp,N
2482,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
2483,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2483,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2484,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2485,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2485,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2485,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2486,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2486,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2486,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2487,1,Coma,Coma states,Neurological disorders NEC,Nerv,N
2488,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2488,2,Product appearance confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2488,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2489,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2489,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2489,3,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
2489,4,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
2490,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2491,1,Brain injury,Structural brain disorders NEC,Structural brain disorders,Nerv,Y
2492,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2493,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2493,2,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
2494,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2494,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
2495,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
2496,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2496,2,Device delivery system issue,Device issues NEC,Device issues,Prod,N
2496,3,Injection site discharge,Injection site reactions,Administration site reactions,Genrl,N
2497,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2498,1,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
2498,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
2499,1,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
2500,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2500,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2501,1,Drug delivery system issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2501,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2501,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2501,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2502,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2502,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2503,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2503,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2503,3,Eye abscess,Eye and eyelid infections,Infections - pathogen unspecified,Infec,N
2503,4,Panophthalmitis,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
2504,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
2505,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
2506,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2506,2,Device mechanical issue,Device physical property and chemical issues,Device issues,Prod,N
2506,3,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
2506,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2506,5,Skin hypertrophy,Skin hyperplasias and hypertrophies,Cornification and dystrophic skin disorders,Skin,N
2507,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2507,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2508,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2508,2,Product preparation error,Product preparation errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2509,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2509,2,Incorrect product administration duration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2510,1,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2511,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2511,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2512,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2512,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2513,1,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2513,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2514,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2514,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2514,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2515,1,Cancer surgery,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
2516,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2517,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2517,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2517,3,Stress,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
2518,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2519,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2519,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2520,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2520,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
2520,3,Gastroenteritis viral,Viral infections NEC,Viral infectious disorders,Infec,N
2521,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2521,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2521,3,Product preparation error,Product preparation errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2522,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
2522,2,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
2522,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
2523,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2523,2,Device delivery system issue,Device issues NEC,Device issues,Prod,N
2523,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2524,1,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
2524,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2524,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2525,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2525,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
2526,1,Hypoglycaemic coma,Coma states,Neurological disorders NEC,Nerv,N
2527,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2527,2,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2528,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2528,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2528,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2529,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2529,2,Device wireless communication issue,Device issues NEC,Device issues,Prod,N
2530,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2530,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2530,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2531,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2531,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2532,1,Headache,Headaches NEC,Headaches,Nerv,N
2532,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2532,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2532,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
2532,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2533,1,Altered state of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2533,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
2533,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2533,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2534,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
2534,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2535,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2535,2,Device information output issue,Device information output issues,Device issues,Prod,N
2535,3,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2535,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2535,5,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2536,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2536,2,Device failure,Device issues NEC,Device issues,Prod,N
2536,3,Device mechanical issue,Device physical property and chemical issues,Device issues,Prod,N
2537,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2537,2,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2537,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2538,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2539,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2539,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2540,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2540,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2541,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2541,2,Device information output issue,Device information output issues,Device issues,Prod,N
2542,1,Device difficult to use,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2542,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
2542,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
2543,1,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2543,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
2543,3,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2544,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2544,2,Device leakage,Device issues NEC,Device issues,Prod,N
2544,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2545,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2546,1,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
2547,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
2548,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2548,2,Device failure,Device issues NEC,Device issues,Prod,N
2548,3,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
2549,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2549,2,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
2549,3,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
2550,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2551,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2551,2,Therapeutic response delayed,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2552,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2552,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2552,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2552,4,Therapeutic product effect delayed,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2553,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2553,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2554,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2555,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
2555,2,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2556,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2556,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2557,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
2557,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
2557,3,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
2558,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2558,2,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2559,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
2559,2,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2560,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2561,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2561,2,Device defective,Device physical property and chemical issues,Device issues,Prod,N
2561,3,Device issue,Device issues NEC,Device issues,Prod,N
2561,4,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2561,5,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2562,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2563,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2563,2,Device defective,Device physical property and chemical issues,Device issues,Prod,N
2564,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2564,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2564,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2565,1,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
2565,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
2566,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2566,2,Device defective,Device physical property and chemical issues,Device issues,Prod,N
2566,3,Device leakage,Device issues NEC,Device issues,Prod,N
2567,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2568,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2568,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2568,3,Product dose omission in error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2569,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
2570,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
2571,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2572,1,Surgery,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
2573,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
2573,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
2574,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2575,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2576,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2577,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2578,1,Device failure,Device issues NEC,Device issues,Prod,N
2578,2,Device leakage,Device issues NEC,Device issues,Prod,N
2578,3,Device loosening,Device issues NEC,Device issues,Prod,N
2578,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2579,1,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
2579,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
2579,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
2579,4,Headache,Headaches NEC,Headaches,Nerv,N
2579,5,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2579,6,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2579,7,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
2579,8,Micturition urgency,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
2579,9,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2579,10,Thirst,Feelings and sensations NEC,General system disorders NEC,Genrl,N
2579,11,Urine ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
2580,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2580,2,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2580,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2581,1,Feeding disorder,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
2581,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2582,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2582,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2582,3,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
2583,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2583,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2583,3,Intentional dose omission,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
2583,4,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
2584,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
2584,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
2585,1,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
2585,2,Lack of injection site rotation,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2586,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2587,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2587,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2588,1,Coeliac disease,Malabsorption syndromes,Malabsorption conditions,Gastr,N
2588,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2589,1,Device issue,Device issues NEC,Device issues,Prod,N
2590,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2590,2,Drug-device incompatibility,Device incompatibility issues,Device issues,Prod,N
2590,3,Increased insulin requirement,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2591,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
2591,2,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2592,1,Headache,Headaches NEC,Headaches,Nerv,N
2593,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2593,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
2593,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2593,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2593,5,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2594,1,Device delivery system issue,Device issues NEC,Device issues,Prod,N
2594,2,Device wireless communication issue,Device issues NEC,Device issues,Prod,N
2594,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2594,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2595,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2596,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
2597,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
2597,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2598,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2598,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2598,3,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2599,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
2599,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2600,1,Device wireless communication issue,Device issues NEC,Device issues,Prod,N
2600,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2601,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2601,2,Disorientation,Confusion and disorientation,Deliria (incl confusion),Psych,N
2601,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2602,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2603,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2604,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2605,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
2605,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2606,1,Abnormal sensation in eye,Ocular sensation disorders,Ocular sensory symptoms NEC,Eye,N
2606,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2606,3,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
2606,4,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
2607,1,Device calibration failure,Device issues NEC,Device issues,Prod,N
2607,2,Device connection issue,Device issues NEC,Device issues,Prod,N
2607,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2608,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2608,2,Device information output issue,Device information output issues,Device issues,Prod,N
2609,1,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
2610,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2610,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2610,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2611,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2611,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2611,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2612,1,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2613,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2614,1,Anti-insulin antibody,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
2614,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2614,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2614,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2614,5,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
2614,6,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
2614,7,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2615,1,Anti-insulin antibody positive,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
2615,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2615,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2616,1,Anti-insulin antibody,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
2616,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2616,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2616,4,Hyperinsulinaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2616,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2616,6,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2617,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2617,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2617,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2618,1,Anti-insulin antibody,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
2618,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2618,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2618,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2619,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2619,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2619,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2620,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2620,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2620,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2620,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2621,1,Device failure,Device issues NEC,Device issues,Prod,N
2621,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2621,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2622,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2622,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
2622,3,Device failure,Device issues NEC,Device issues,Prod,N
2622,4,Device issue,Device issues NEC,Device issues,Prod,N
2623,1,Brain fog,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2623,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2623,3,Headache,Headaches NEC,Headaches,Nerv,N
2623,4,Menopausal symptoms,Menopausal effects NEC,Menopause related conditions,Repro,N
2623,5,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
2624,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2624,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2624,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2625,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2626,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2627,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2628,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2628,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
2628,3,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2628,4,Renal injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
2628,5,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2629,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2629,2,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2630,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2631,1,Inflammation,Inflammations,General system disorders NEC,Genrl,N
2632,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2632,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2633,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2634,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2634,2,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
2635,1,Device information output issue,Device information output issues,Device issues,Prod,N
2635,2,Device wireless communication issue,Device issues NEC,Device issues,Prod,N
2635,3,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2636,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2636,2,Device failure,Device issues NEC,Device issues,Prod,N
2637,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2637,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
2637,3,Device failure,Device issues NEC,Device issues,Prod,N
2638,1,Device failure,Device issues NEC,Device issues,Prod,N
2638,2,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2638,3,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2639,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2639,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2640,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2641,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2641,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2642,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2643,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2643,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2643,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2644,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2645,1,Postprandial hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2646,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2646,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2647,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2647,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
2647,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
2648,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2649,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2650,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2651,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2651,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2651,3,Physical product label issue,Product label issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2651,4,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2652,1,Eye movement disorder,Ocular nerve and muscle disorders,Ocular neuromuscular disorders,Eye,N
2652,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
2653,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
2654,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2654,2,Product container issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2654,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2655,1,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
2656,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
2656,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2657,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,Y
2658,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2659,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2659,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2659,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2660,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2660,2,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
2660,3,Drug delivery system issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2660,4,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
2661,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2662,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2662,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2663,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2663,2,Gastroenteritis viral,Viral infections NEC,Viral infectious disorders,Infec,N
2664,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2664,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2664,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2665,1,Device delivery system issue,Device issues NEC,Device issues,Prod,N
2665,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2665,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2666,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
2667,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2668,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
2669,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2669,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2669,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2670,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2670,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2671,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
2671,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
2671,3,Device leakage,Device issues NEC,Device issues,Prod,N
2671,4,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
2671,5,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2672,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2672,2,Device delivery system issue,Device issues NEC,Device issues,Prod,N
2673,1,Abdominal infection,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
2673,2,Poor quality product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2674,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2674,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2674,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2674,4,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2674,5,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2675,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2675,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2676,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2676,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2677,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2677,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2678,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
2678,2,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
2679,1,Device mechanical issue,Device physical property and chemical issues,Device issues,Prod,N
2679,2,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
2680,1,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2681,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2682,1,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2682,2,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2683,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2683,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2684,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2684,2,Device loosening,Device issues NEC,Device issues,Prod,N
2684,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2685,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2685,2,Device delivery system issue,Device issues NEC,Device issues,Prod,N
2685,3,Device failure,Device issues NEC,Device issues,Prod,N
2686,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2687,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2687,2,Device failure,Device issues NEC,Device issues,Prod,N
2687,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
2688,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2688,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2689,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2689,2,Blood ketone body present,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
2689,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2690,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2690,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2690,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2690,4,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2691,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2691,2,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2691,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2692,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2692,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2692,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2693,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2693,2,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2693,3,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2694,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2694,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
2694,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2694,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
2695,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2695,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2696,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2696,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
2696,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
2697,1,Anti-insulin antibody positive,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
2697,2,Diabetic retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
2697,3,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2698,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
2698,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
2698,3,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
2698,4,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
2698,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2698,6,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
2698,7,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
2699,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2699,2,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2700,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2701,1,Device information output issue,Device information output issues,Device issues,Prod,N
2701,2,Device wireless communication issue,Device issues NEC,Device issues,Prod,N
2701,3,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2702,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2703,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2704,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2705,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2705,2,Device wireless communication issue,Device issues NEC,Device issues,Prod,N
2706,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2706,2,Intentional dose omission,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
2707,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2707,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2707,3,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
2708,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2708,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
2708,3,Device issue,Device issues NEC,Device issues,Prod,N
2708,4,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
2708,5,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2708,6,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2709,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2709,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
2709,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2710,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2710,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2710,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2710,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2711,1,Device mechanical issue,Device physical property and chemical issues,Device issues,Prod,N
2711,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
2712,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
2712,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
2712,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2712,4,Tension headache,Headaches NEC,Headaches,Nerv,N
2713,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2713,2,Increased insulin requirement,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2713,3,Insulin resistance,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2714,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2714,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2714,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2714,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2714,5,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2715,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
2715,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2716,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
2716,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
2716,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2716,4,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2717,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2717,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2718,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2718,2,Device issue,Device issues NEC,Device issues,Prod,N
2718,3,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2718,4,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2719,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2719,2,Device delivery system issue,Device issues NEC,Device issues,Prod,N
2719,3,Device dislocation,Device issues NEC,Device issues,Prod,N
2719,4,Device failure,Device issues NEC,Device issues,Prod,N
2720,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
2720,2,Headache,Headaches NEC,Headaches,Nerv,N
2720,3,Neck pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
2720,4,Throat tightness,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
2721,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2721,2,Suspected counterfeit product,"Counterfeit, falsified and substandard products","Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2721,3,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
2722,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2722,2,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2723,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2723,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2723,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2724,1,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2724,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
2725,1,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
2725,2,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2725,3,Product appearance confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2725,4,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2726,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2727,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2728,1,Device failure,Device issues NEC,Device issues,Prod,N
2728,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2728,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2729,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2730,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
2730,2,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
2731,1,Hypoaesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
2732,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2732,2,Device issue,Device issues NEC,Device issues,Prod,N
2732,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
2733,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2733,2,Device delivery system issue,Device issues NEC,Device issues,Prod,N
2733,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2734,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2734,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2734,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2735,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2736,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
2736,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
2737,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2737,2,Device leakage,Device issues NEC,Device issues,Prod,N
2738,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2738,2,Blood ketone body increased,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
2739,1,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2739,2,Device delivery system issue,Device issues NEC,Device issues,Prod,N
2739,3,Device issue,Device issues NEC,Device issues,Prod,N
2739,4,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2740,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2741,1,Dementia,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
2742,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2742,2,Product leakage,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
2743,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2743,2,Device failure,Device issues NEC,Device issues,Prod,N
2743,3,Device issue,Device issues NEC,Device issues,Prod,N
2744,1,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2744,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
2745,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2746,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2746,2,Device failure,Device issues NEC,Device issues,Prod,N
2746,3,Device information output issue,Device information output issues,Device issues,Prod,N
2747,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
2747,2,Device information output issue,Device information output issues,Device issues,Prod,N
2747,3,Device leakage,Device issues NEC,Device issues,Prod,N
2747,4,Device malfunction,Device malfunction events NEC,Device issues,Prod,N
2747,5,Device power source issue,Device malfunction events NEC,Device issues,Prod,N
2748,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
2749,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
